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ABSTRACT 
Healthcare expenses have been on the rise for decades. One of the key areas 
contributing to this ever-expanding growth is medicine expenses. Medicines are 
required to maintain a sustainable health system in a world of aging populations and 
pandemics. Novel medicines combat diseases previously considered incurable, and 
medicines help people with chronic conditions to live normal lives. Furthermore, in 
emerging economies, pharmacies are often the first and only interface to healthcare 
services, whereby other medical services are scarce or expensive. However, 
medicines are associated with costs. To maintain a sustainable health system, the 
growing expenses have to be managed. 
There are different ways of controlling medicine expenses. In this age of 
digitalization, when multiple sectors have been disrupted by digital technologies, it can 
be argued that digital technologies have a role to play in the medicine supply field. 
This intersection of medicine supply and information systems has been, however, 
sparsely studied. This thesis seeks to fill this research gap by exploring the medicine 
supply chain and discovering obstacles and bottlenecks across the chain. The study 
also intends to identify how information systems and digital technologies can be 
utilized to remediate the problems and facilitate an efficient medicine supply chain. 
The research approaches the medicine supply chain arena through the medicine 
supply chain concept. The supply chain is a highly complex world involving the 
pharmaceutical industry and the distribution, prescription and dispensing of 
medicines. This research examines this arena through cases from across the supply 
chain covered in four separate studies and related articles. The supply chain concept 
and the scene are set in one of the studies, followed by studies on the digitalization 
of pharmacies, medicine waste management in hospitals and the digitalization of the 
plasma derivatives supply chain. 
The results of this research illustrate that the main role of digital technology in 
the management of the medicine supply chain relates to managing several 
information asymmetries across the chain. The key is to increase transparency 
between various stakeholders in the chain through novel digital solutions. Currently, 
the supply chain processes are largely based on rules of thumb rather than facts and 
evidence, and this should be addressed to maintain a sustainable chain and, 
subsequently, a sustainable health system. 
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TIIVISTELMÄ 
Terveydenhuollon kulut ovat nousseet vuosikymmenien ajan. Lääkekulut 
muodostavat merkittävän osan terveysmenoista. Lääkkeitä tarvitaan kestävän 
terveydenhuoltojärjestelmän ylläpitämiseksi: lääkkeillä voidaan hoitaa aiemmin 
parantumattomia sairauksia sekä tukea ikääntyvää väestöä. Kehittyvissä talouksissa 
apteekit ovat usein myös ensimmäinen ja ainoa yhteys terveyspalveluihin. 
Lääkkeillä ja niiden kehittämisellä on kuitenkin kulunsa ja kestävän 
terveydenhuollon järjestelmän ylläpitämiseksi onkin kyettävä ymmärtämään ja 
hallitsemaan lääkekuluja. 
Lääkekuluja voidaan hallita eri tavoin. Digitalisaatiolla voidaan ajatella olevan 
tässä myös roolinsa – useat toimialathan ovat muuttuneet merkittävästi digitaalisten 
ratkaisujen myötä. Digitalisaation ja tietojärjestelmien merkitystä lääkejakelussa ei 
olla kuitenkaan tutkittu laajasti. Tämän väitöskirjan tarkoituksena on täyttää tätä 
tutkimusaukkoa perehtyen lääkejakelun prosesseihin, niihin liittyviin esteisiin ja 
pullonkauloihin sekä digitaalisiin ratkaisuihin, joilla lääkejakelua voidaan tukea ja 
tehostaa. 
Tutkimus lähestyy aluetta mallintaen lääkejakeluketjua. Lääkejakeluketju on 
monimutkainen globaali systeemi, joka kattaa toimijoita mm. lääketeollisuudesta, 
jakelusta ja logistiikasta, terveydenhuollosta ja vähittäismyynnistä. Tässä 
tutkimuksessa jakeluketjua tarkastellaan neljän tutkimuksen kautta, jotka liittyvät 
lääkejakeluketjun eri osiin. Aluksi esitellään lääkejakeluketjukonsepti, jota 
seuraavat tutkimukset apteekkien digitalisoinnista, sairaalan lääkehuollosta ja 
veriplasmatuotteiden toimitusketjun digitalisoinnista. 
Tämän tutkimuksen tulokset havainnollistavat, että digitaalisten ratkaisujen 
päärooli lääkejakeluketjun hallinnassa liittyy varsinkin informaatiosymmetrioiden 
hallintaan sekä tiedon avoimuuden ja läpinäkyvyyden lisäämiseen ketjun eri 
sidosryhmien välillä. Nykyisin lääkejakeluketjun prosesseja leimaa epävarmuus ja 
faktoihin perustuva päätöksenteko on vaikeaa, mikä heikentää tehokkaan 
lääkejakelun ylläpitämistä. 
ASIASANAT: Lääkejakelutketju, digitalisointi, lääkejätehuolto, lohkoketju, e-
resepti, informaatioepäsymmetria  
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Healthcare expenses have continued to increase significantly over the past decades. 
Annual per capita expenditure almost doubled from 1970 to 2016 (OECD, 2019b). 
There is no indication this trend will change, and it is, undoubtedly, a societal issue 
that needs to be solved. The question is how to maintain a sustainable health system. 
There are several factors contributing to this trend. One of them is the aging 
population in the developed world. People live longer, and when they become old, 
they require more health services. Countries such as Finland try to solve the issue, 
whereby there is an aging demography and increasingly fewer taxpayers, while the 
requirement is still to run a quality healthcare system. This turns the issue of rising 
health expenses into a question of productivity. 
Health systems vary depending on the country. The highest spending country has 
traditionally been the United States, which spends twice as much as other high-
income countries (Papanicolas, et al., 2018). The suggested reasons for this include 
population growth and aging, chronic disease prevalence (Dieleman, et al., 2016) 
and increasing prices in the healthcare and pharmaceutical market (Papanicolas, et 
al., 2018). 
The topic is complex, and there are varying and often conflicting explanations 
for the ever-increasing expenditure. For example, the economic growth in the 
developing world typically leads to increased pollution and, therefore, may degrade 
health and increase healthcare expenses (Wang, et al., 2015). 
Some authors have also questioned the importance of the aging population and 
suggest that reasons such as quality of healthcare, lifestyle and social protection are 
key factors contributing to growing expenditure (van den Heuvel & Olaroiu, 2017). 
Some other authors have highlighted the importance of social spending (Papanicolas, 
et al., 2018). For example, these authors suggest that the main drivers for expenditure 
growth in the United States include higher price levels of goods and labor than in 
other high-income countries (Papanicolas, et al., 2018). Nevertheless, this discussion 
underlines the uncertain and complex nature of the domain – whereby information 
is seldom available in an open and unambiguous manner, often due to strict 
regulations for health-related data. 
Introduction 
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Pharmaceutical breakthroughs have also had a role to play. The invention of 
antibiotics led to preventing deaths from infections, which subsequently enabled 
people living longer and rather suffering from heart diseases and cancers due to 
longer life (Weisbrod & LaMay, 1999). These are costly conditions, given they are 
long-term and chronic and may require intensive treatment. 
This illustrates the difficult nature of healthcare services: putting a price tag on 
health leads to difficult discussions on who should pay for what and who should be 
treated. To illustrate the paradoxical nature, consider smokers – a smoker may 
generate more healthcare costs during a short period, whereas a nonsmoker will 
accumulate more costs during the 10–15 years he is outliving the smoker (Kleinke, 
2001). Health expenditure is also a complex issue for politicians, and governments 
may fail when trying to solve it (Milne, 2019). 
Various solutions have been suggested. One of the key elements in managing the 
increasing healthcare spending is, however, the medication. Broadly speaking, it is 
often argued that having people consume medicines at home and reducing the 
amount of hospital stays is cost-effective (Kleinke, 2001). Putting it bluntly, the aim 
is to maintain elderly people and those with chronic conditions at home for as long 
as possible. However, it should be noted that the actual impact, if any, of the 
medication to healthcare expenses and decreasing hospital stays is challenging to 
isolate or prove. 
From the OECD (2020) health expenditure data, as illustrated in Figure 1, it can 
be noted that pharmaceutical expenditure has increased moderately compared to 
overall health expenses. The chart depicts the development of pharmaceutical and 
healthcare expenses as percentages of gross domestic product and the development 
of hospital stays in days. It should be noted that the figures are incomplete, as they 
do not include pharmaceuticals consumed in hospitals and for day-care treatment 
(OECD, 2019a). It can be observed that hospital stays have decreased over the past 
decades. However, medication is only one potential influencing factor, and its impact 




Figure 1. OECD health expenditure (OECD, 2020). 
It is suggested that low-cost essential medicines treating common health problems 
are key to maintaining a cost-effective health system (Management Sciences for 
Health, 2012). However, medicines do not come without costs. 
The volume of medicines consumed today is staggering. There are more than 
4,000 pharmaceuticals used in healthcare (Arnold, et al., 2014). The medicine 
expenses account for roughly 20% of overall health expenses in OECD countries 
(OECD, 2017). Considering the four largest EU markets – France, Germany, Italy, 
Spain – and the UK, the medicine expenses vary between 11% and 19% of the total 
healthcare expenditure (Espin, et al., 2018). According to Newhouse (1992), this is 
unlikely to decrease: he suggests that half of the healthcare expense increase is due 
to technological advances and innovation, including those relating to 
pharmaceuticals. This is not an unfounded position: it is suggested that new specialty 
drugs, such as oncological drugs, comprise one-third of total pharmaceutical 
spending (Belloni, et al., 2016). It is, however, estimated that new drugs have had an 
impact on the reduction of life years lost in a cost-efficient manner. For example, 
Lichtenberg (1998) suggested that an R&D investment of USD 15 billion in the 
pharmaceutical industry saves 1.6 million lives annually, which can be valued at 
USD 27 billion. However, the prices of new drugs tend to be high, and it is not always 
clear whether the benefit exceeds the costs (Belloni, et al., 2016). 
Introduction 
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Another aspect is adverse drug reactions (ADRs). For example, the U.S. Food 
and Drug Administration (FDA) reported a significant, almost threefold, increase in 
ADRs between 1998 and 2005 (Light & Lexchin, 2021). One factor is the aging 
population and the growth in terms of polymedicated patients. ADRs may be fatal, 
and the associated costs are scarcely included in medicine expense estimates (Light 
& Lexchin, 2021). 
Nevertheless, global pharmaceutical spending is on the growth path, which does 
not seem to be slowing down. It is estimated that global spending will reach 
USD 1.5 trillion by 2021, which is USD 370 billion more than in 2016 and almost 
double the spending in 2007 (QuintilesIMS, 2016). Considering Europe, the publicly 
funded part of medication expenses varies from Finland’s 50% to Germany’s 70% 
(Aanestad, et al., 2017a). 
Authorities ought to monitor the development of these costs meticulously to keep 
them under control. For example, in Finland, there were 30.8 million prescriptions 
processed in 1995, while in 2018, the amount had risen to 63.3 million, of which 
43.43 million were publicly subsidized  (Lääkealan turvallisuus- ja kehittämiskeskus 
Fimea ja Kansaneläkelaitos, 2019; Kansaneläkelaitos, 2020). 
The factors affecting pharmaceutical spending typically includes, in addition to 
the launch of new drugs, changing prices and quantities (Mousnad, et al., 2014). 
Various policy interventions can be used to mitigate the spending, including those 
steering the pricing of medicines in different markets. However, this is not always 
straightforward, as the pharmaceutical industry must stay incentivized to maintain 
an adequate level of R&D investment. 
The delivery channels for medicines include pharmacies and hospitals. This 
forms an alternative endpoint for evaluating expenditure: Can the efficiency of the 
supply and delivery of medicines be increased? Medicine waste is a relevant example 
here – for instance, the estimated loss caused by prescription medicine waste in 
Finland is between EUR 95 million and EUR 125 million (Apteekkariliitto, 2016). 
Waste is a symptom of an inefficient delivery system and an example of areas that, 
if remediated, would contribute to lowered pharmaceutical expenditure. However, 
how can these pain points be addressed? Are there tools that can be used to remediate 
these inefficiencies? 
Digitalization has been one of the buzzwords through the 2000s. It denotes the 
sociotechnical, comprehensive transformation organizations undergo when 
deploying digital technologies and modifying processes and organizations around 
them (Tilson, et al., 2010). Digitalization has disrupted several sectors, including 
finance, hospitality and transportation. One of the key aspects digitalization is 
commonly understood to address is productivity, which is expected to increase in 
various sectors (Pohjola, 2014). Perhaps digitalization also has a role to play in the 
medicine supply chain. 
Teijo Peltoniemi 
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1.2 The market profile and research gaps 
The healthcare market has been widely researched. It is a peculiar market, as proven 
by Arrow (1963) in his seminal article. One of the key findings is that the market is 
heavily impacted by information asymmetries and policy interventions. Patients 
have significantly less information on treatments than physicians, physicians or 
insurers rarely know whether patients follow prescriptions and so forth. Therefore, 
it is typically understood that the market cannot be left to self-regulate. Instead, the 
information asymmetries must be reduced by tight regulations. 
The pharmaceutical market can be considered a closely related entity, which has 
been widely researched as well. Newhouse (1992) suggested that several decades of 
continuing expansion of healthcare costs have been heavily impacted by the 
invention of new medicines and healthcare technology. Again, information 
asymmetries come into play. One manifestation is patient adherence – that is, 
whether the patient follows the prescription and consumes the right medicines at the 
right time. This is hard to monitor (Martin, et al., 2005). 
However, broadly speaking, the usual viewpoints for the research on healthcare 
and pharmaceutical markets are those relating to economics, policy and medical 
perspectives. Information and digital technologies have also been studied in relation 
to these markets, and they have been understood as a key factor bringing productivity 
gains (Aanestad, et al., 2017b). Some dominant research strands can be identified. 
One is digital health research, which is approaching the area from the computer 
science point of view. The current focus is on solutions such as mobile health and 
wearables (Gray & Gilbert, 2018). Another closely related research area is health 
informatics, which concerns managing data such as those related to molecular 
medicine or population health indicators (Gray & Gilbert, 2018). According to a 
broader definition, “It [health informatics] concerns the use of information and 
communication technologies (ICTs) for health and in health care” (Bath, 2008, p. 
501). 
Another point of view is that of information systems (IS) research, in which the 
health information systems (HIS) arena can be found. Information systems science 
(ISS) is typically considered a social science field. ISS concerns how organizations 
and technologies interact and the impact of technology on people. Therefore, the 
research approach is typically softer than hard science–based computer science. 
However, few or none of these research strands touch upon pharmaceutical or 
medicine supply, and it can be concluded that research combining medicine supply 
and IS is scarce. One particular area that can be understood to be relevant here is 
electronic prescription (ePrescription), which has been studied in numerous accounts 
(e.g. (Abramson, et al., 2011; Caldwell & Power, 2011; Johnson & Lehmann, 2013)). 
However, research comprehensively exploring the medicine supply and from the IS 
standpoint is currently lacking. 
Introduction 
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To illustrate this, if the Finnish national library catalog is searched for doctoral 
theses (Melinda, https://melinda.kansalliskirjasto.fi) with search terms such as 
“medicine,” “pharmaceutical,” “supply” and “delivery,” combined with 
“information systems,” and the same in Finnish, no theses can be found, with scarce 
publications overall. None of these comprehensively examine the medicine supply 
chain from the IS point of view. 
When examining some recent international IS conferences, the results are 
similar. Investigating articles from the proceedings of the European Conference on 
Information Systems and Hawaii International Conference on System Sciences 
(2015 and 2016), 136 HIS articles were identified (Peltoniemi, 2018). Of these, only 
seven touch upon medicine delivery in some way: 
• Five articles are on medication adherence. 
• One is on consumer health expressions in terms of ADRs. 
• One is on a flu monitoring system based on mining ePrescription data. 
The emphasis and themes of other related conferences, such as the World 
Congress on Medical Informatics (MEDINFO, Global) and Medical Informatics 
Europe, have been reviewed in studies. For example, a study investigating 
conference articles between 2007 and 2017 lists various key themes, such as 
electronic health records, but the medicine supply chain is not one of them (Jia, et 
al., 2018). This can be verified through examining the MEDINFO 2017 proceedings 
– one article that discusses medicine supply and data can be identified, but this is 
restricted to the point of view of clinical systems in a hospital (Lichtner & Cornford, 
2017). 
Based on this, it can be argued that the medicine supply arena has been sparsely 
studied from the IS perspective, and there is an opening for novel research. Whereas 
many other healthcare domains are well studied and there is good coverage of HIS 
research available, the intersecting arena of medicine supply chain and IS remains 
blurry. ePrescription-related research may elucidate certain parts of medicine supply, 
but research on the end-to-end medicine supply chain and how various parts of the 
chain interconnect is scarce, nor are there studies on current challenges and how this 
vital concept can be improved. During the present times of pandemics and aging 
populations, it is of utmost significance to ensure an efficient medicine supply chain. 
IS and digital technologies, undoubtedly, have a part in this concept; hence, the 




1.3 Purpose of the thesis and the main research 
question 
To address the current research gap, this study examined the medicine supply chain 
and identified some major pain points that hinder the efficient delivery of medicines, 
as well as investigated how IS are used to remediate these pain points. In terms of 
IS, the emphasis was on digital technology and digitalization. Specifically, those 
systemic or social innovations that are driven by digital technologies were sought to 
be identified. It is suggested that healthcare transformation requires systemic change 
– given it is a vast ecosystem – whereby (ideally) several services are integrated in a 
patient-centric manner (Virtanen, et al., 2017). 
The initial research interest was to understand the digitalization of the medicine 
supply chain from the eCommerce viewpoint, as a subarea of the wider digitalization 
of the retail and consumer goods markets. The retail sector has been digitalizing, in 
the 2010s, at an accelerating pace, which is manifested through the success of online 
marketplaces such as Amazon and the decline of traditional brick-and-mortar 
retailing. 
As the peculiarities of the market began to become clear, the emphasis of this 
study was re-aimed at the downstream of the market – that is, the delivery of 
medicines to patients in pharmacies and hospitals. This choice was made partly due 
to convenience reasons, as the access to research targets in the downstream is easier. 
While focusing on the downstream in medicine supply, the aim was, however, to 
thoroughly understand the supply chain, and the associated original articles also 
cover the upstream – that is, the pharmaceutical industry. 
The research theme can be summarized as follows: what kind of obstacles and 
bottlenecks there are in the medicine delivery arena and how those can be 
remediated with digital technologies. The goal of this research was to model the 
delivery chain and study it from this viewpoint. 
As shall shortly be seen, the characteristics of the medicine supply chain include 
that it is pervaded by incomplete and uncertain information, which hinders 
optimizing the supply chain, and that it is a complex sociotechnical environment. 
These are the two main perspectives in this thesis and the related research. 
1.4 Structure of this dissertation 
Based on the four studies conducted in this research, an end-to-end model for 
medicine supply is suggested. This is depicted in Figure 2. The model illustrates the 
main actors and entities across the supply chain. The figure also shows how the 




Figure 2. Model for medicine supply and the articles in the dissertation. 
Regarding the ever-increasing healthcare expenses and, specifically, medicine 
expenses, this model can be used to identify bottlenecks and, conversely, areas of 
improvement. 
The research and subsequent articles covered in this thesis consider the two 
characteristics mentioned above. The research contributes to the field by revealing 
various challenges in different parts of the supply chain and suggesting solutions and 
further research topics for these challenges. The articles describe four studies that 
were researched for this thesis. Given the complexity of the arena, it is impossible to 
cover the entire supply chain in one thesis; however, the cases still represent several 
parts of the chain. The focus was on the actual operational level; hence, regulatory 
and financing processes, for example, were left for subsequent research projects. 
Article I: This article lays the foundation for this thesis by outlining the concept 
and structure of the medicine supply chain and identifying key concepts relating to 
it. The key challenge it identifies is the information asymmetry that pervades the 
healthcare and pharmaceutical markets. Through targeted literature reviews, the 
article identifies several solutions currently used, or planned to be used, to mitigate 
the information asymmetry problem. For example, from the patient viewpoint, the 
key solutions include automatic medicine dispensing, ePrescription, electronic 
patient records, generic substitution, and reference price systems. These are 
interlinked and often powered by digital technologies. These solutions drive 
medicine supply today, but it is clear that new means are required going forward, 
given the occurrence of pandemics and aging populations. Value and evidence-based 
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approaches, patient empowerment and new technologies such as blockchain can 
enhance medicine supply through managing the associated information 
asymmetries. 
Article II: Pharmacies are key entities in the medicine supply chain. This article 
views how the pharmacy sector in Finland has been undergoing a vast transformation 
in the 2010s due to the launch of ePrescription and related new workflows. The 
article takes a sociotechnic view and suggests that the changes in the pharmacy 
dispensing processes are an example of successful digitalization within the medicine 
supply chain. The research draws on data collected from pharmacy dispensing 
processes while observing them prior to and after the launch of ePrescription. The 
article reveals how mandated adoption of the new technology has spawned various 
streams of other changes in the working processes, whereby the processes have been 
renewed rather than adapted. 
Article III: This study focuses on the medicine supply chain in a hospital. It 
outlines the related environment of the process, organization and technologies and 
identifies medicine wastage as one of the key challenges accumulating medicine-
related costs in hospitals. This research is based on observations, interviews and a 
survey and elucidates an uncertain territory whereby hospital staff must cope with 
inconsistent information and less-than-optimal IT systems. This is an example of a 
part of the medicine supply chain where digitalization has not happened; the 
processes remain manual and administratively burdening, causing productivity 
losses. 
Article IV: This article focuses on the upstream of the medicine supply chain, 
exploring challenges the pharmaceutical industry is facing and suggesting a digital 
solution. The article specifically investigates the blood plasma market and identifies 
various risks in the current setting, including ethical and supply chain risks. The 
suggested solution is based on distributed ledger technology (DLT), illustrating how 
a digital technology has the capability to transform an established market. 
 
2 Setting the Scene – Previous 
Literature Review and Conceptual 
Framework 
2.1. Defining key concepts and terms 
2.1.1 Medicine as a term 
A medicine is defined as “a substance or preparation used in the treatment of illness; 
a drug; esp. one taken by mouth. Also: such substances generally.” (Oxford English 
Dictionary, 2020). This definition clearly suggests that “medicine” and “drug” are 
synonymous terms. The same dictionary defines a drug as “a natural or synthetic 
substance used in the prevention or treatment of disease, a medicine,” on the other 
hand, is “a substance with intoxicating, stimulant, or narcotic effects used for 
cultural, recreational, or other non-medicinal purposes.” To avoid confusion with 
illegal drugs, the term “medicine” is used in this thesis. “Medicine” is not entirely 
unambiguous as a term since it can also refer to different things, such as the medical 
science and methods practiced by physicians. However, this unambiguity is less 
significant than that related to the term “drug.” In Finland, there is no such ambiguity 
since the word lääke refers to medicine as a medicinal product, whereas lääketiede 
refers to medicine as a science or practice. 
The terms medicine and drug can, however, be used interchangeably. In the US, 
the latter seems to be de facto, as can be inferred based on the name of the related 
authority (FDA). In Finland, the counterpart is named the Finnish Medicines Agency 
(Fimea). The third related term is “pharmaceutical.” This derives originally from the 
Greek word referring to druggist – that is, it refers to “pharmacy” and, particularly, 
the sale of medicines (Oxford English Dictionary, 2020). 
2.1.2 Definition by authorities 
Regulations can be used as a basis for specifying the meaning of medicine. 
According to the European Commission (Directive 2001/83/EC), a medicinal 
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product refers to “any substance or combination of substances presented as having 
properties for treating or preventing disease in human beings; or any substance or 
combination of substances which may be used in or administered to human beings 
either with a view to restoring, correcting or modifying physiological functions by 
exerting a pharmacological, immunological or metabolic action, or to making a 
medical diagnosis.” Finnish law follows the European Commission directive and 
includes veterinarian products (Lääkelaki [Medicines Act] 395/1987). 
Fimea is responsible for maintaining a catalog that contains formally 
acknowledged medicines in Finland (Fimea, 2020). The catalog also has a section 
for herb-based substances that can be used as medicines – which, in these cases, are 
treated as medicinal products by Finnish law (Lääkealan turvallisuus- ja 
kehittämiskeskuksen päätös lääkeluettelosta [Finnish Medicines Agency's decision 
on medicine catalogue] 19.3.2019/415). Furthermore, medically consumed 
substances whose composition, manufacturing method or mode of action differ from 
those of traditional medicines are treated as medicines. These include radioactive 
medicinal products, allergenic products, vaccines, medicinal gases, and blood and 
blood plasma–based products (Fimea, 2020). 
Medicinal products and medical devices are closely related and often get mixed 
up. The regulation for the latter was introduced more recently than for the former, 
and many products previously treated as medicines have been transferred to the 
category of medical devices (Medicines and Healthcare Products Regulatory 
Agency, 2021). These include wound dressings, surgical materials and irrigation 
solutions, as well medical imaging equipment. Devices that incorporate a medicine 
and the instrument used to administer it are treated under the medicine legislation. 
The classification between medicinal products and medical devices is not always 
straightforward. The European Commission has specified a set of regulations for 
medical devices and argues, “Medical devices and In vitro diagnostic medical 
devices (IVDs) have a fundamental role in saving lives” (European Commission, 
2020). There are, in fact, multiple European Commission directives to regulate this 
field: Medical Devices, In Vitro Diagnostic Medical Devices and Active Implantable 
Medical Devices directives (Medicines and Healthcare Products Regulatory Agency, 
2021). 
Furthermore, terms such as “product” and “use” are often used to mean different 
things (Langedijk, et al., 2015). A product, for example, can mean a pharmaceutical 
ingredient or a consumption-ready dosage. Another line of confusion comes from 
substitutes such as biosimilars; are those biological compositions resembling 
biological medicines or medicines on their own? In this thesis, however, the review 
is restricted to top-level ontology and does not address these questions. 
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2.1.3 What is treated as medicine in a hospital? 
The duties of pharmaceutical services in a hospital include the following (Hospital 
District of Southwest Finland, 2020): 
• Pharmaceutical logistics 
• Manufacturing medication 
• Injections and infusions individually prepared for the treatment of cancer 
• The pharmaceutical responsibility of preparing radioactive medication 
• The logistics of clinical medicine trials and the preparation of medicine 
• Pharmaceutical services in the wards. 
The duties of hospital pharmacies are regulated by law in Finland (Fimea, 2018b). 
2.2 Medicine supply chain 
Supply chain is the end-to-end process from the factory to the customer (Clauson, et 
al., 2018). The pharmaceutical or medicine supply chain refers to the path a medicine 
takes when traversing from the manufacturing and packaging plants to be distributed 
and dispensed to patients. The organizations involved include public and private 
sector actors at different regional levels (Management Sciences for Health, 2012). 
Imran, et al. (2017) introduced a two-channel medicine supply chain model whereby 
one channel goes from manufacturers through pharmacies and clinics to patients and 
the other through hospitals and hospital pharmacies. Authorities such as health 
departments come to play in a related integrated healthcare system. 
Regarding acquiring medicines in the downstream, over-the-counter (OTC) 
medicines and prescription medicines can often be separated in terms of financing. 
For example, in Finland, prescription medicines are largely subsidized for the 
consumer, whereas OTC medicines are paid for out of pocket (Pharmaceutical 
Pricing Board, 2020). OTC medicines refer to medicines one can buy without a 
prescription (FDA, 2018b). Financing in the Finnish pharmaceutical market is 
discussed more broadly in Section 2.5. 
The World Health Organization (WHO) defined the medicines management 
cycle, which comprises selection, quantification and forecasting, procurement, 
storage and distribution as main elements (WHO, 2015b). According to the WHO, 
the medicine supply chain is an integral part of the overall health system, and 




Burns et al. (2002, p. 4) discussed a value chain rather than a supply chain, 
whereby each step in the chain adds value to the end product provisioned to the 
customer, i.e. the patient. The main actors include the following: 
• Payers: e.g. government, employers and patients. 
• Fiscal intermediaries: e.g. insurers. 
• Providers: e.g. healthcare service providers, physicians and pharmacies. 
• Purchasers: e.g. wholesalers. 
• Producers: e.g. medicine manufacturers (also called pharmaceuticals).  
Supply chain and value chain are closely related terms and are often used 
interchangeably (e.g. (Rossetti, Handfield, & Dooley, 2011)). A supply chain 
concerns a virtual organization producing and distributing goods – in contrast to a 
vertical organization, which uses end-to-end insourcing (Burns, et al., 2002). It is 
easy to see that a supply chain can also be a value chain, whereby each of the nodes 
in the chain contributes (i.e. adds value) to the delivery of the goods. In this thesis, 
these terms are used interchangeably, and they may also refer to the medicine 
delivery chain. 
Financing is an important aspect of medicine supply, and there are six main 
models (Management Sciences for Health, 2012, p. 8): 
1. Fully public: The state is responsible for the medicine supply in its entirety, 
including financing, procuring and distributing. 
2. Private supply to public health services: Medicines are publicly funded and 
delivered directly by suppliers to public health service providers. 
3. Social health insurance systems: The acquisition of medicines that are dispensed 
in private pharmacies is subsidized from public funds and social health 
insurance. 
4. Private financing and public supply: Patients pay for medicines supplied and 
dispensed by public sector service providers. 
5. State wholesale monopoly: Public sector monopolized importation and 
distribution of medicines to private pharmacies. 
6. Fully private: Patients pay the entire cost of the medicine they acquire from 
private pharmacies. 
There is country-specific variance in the supply chain approach. The WHO 
recognizes two models – push and pull (whereby pull is the mainstream way, 
according to which local-level distribution entities order medicines from higher-
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level central distribution centers) (WHO, 2015b). Whereas the pull model requires 
the lower level to be capable of calculating and forecasting the demand, which 
according to the WHO is a human task, in the push model, a central entity pushes 
medicines to the lower level. This can be used, for example, with a limited list of 
medicines in emergency circumstances or if there is no consumption history data. 
The wholesale level of the supply chain can vary as well. For example, the supply 
chain in Finland has traditionally been dominated by two wholesalers. Whereas there 
are more than 100 wholesaling organizations in Finland, only two have maintained 
stocks and downstream distribution channels, while the rest have only imported 
medicines. Medicine distribution has been carried out through a single wholesale 
channel, whereby a particular medicine has been solely available for pharmacies 
from the designated wholesaler rather than multiple wholesalers (Meriluoto, 2018). 
This setup is, however, undergoing reconsideration. For example, some 
pharmaceutical manufacturers have already utilized multiple wholesale channels in 
cases of supply chain disruptions at the wholesale level (Meriluoto, 2018). The 
single-channel system is a commonly agreed practice within the industry, which is 
not based on strict legal requirements (Kilpailu- ja kuluttajavirasto, 2000). 
The one-channel distribution concept raises questions about the competitiveness 
of the market. In other countries, pharmaceutical companies can utilize multiple 
distributors, and pharmacies and hospitals put medicine orders out to tender. Sweden 
used to have a one-channel distribution system as well, until it was dismantled as a 
part of wider deregulation of the pharmaceutical market in 2009 (Rönnback, 2018). 
Whereas the Finnish Competition and Consumer Authority has assessed the one-
channel distribution setup multiple times (e.g. (Kilpailu- ja kuluttajavirasto, 2000), 
(Kilpailu- ja kuluttajavirasto, 2012)), the agency has, each time, cleared it as 
compliant with competition regulations. The medicine wholesale sector has seen 
consolidation in other parts of the EU as well; however, no other member country 
has a one-channel distribution system (Kanavos, et al., 2011). 
The one-channel concept has been justified as an efficient and secure system. It 
is suggested that the wholesale margins in Finland are among the lowest in Europe 
(Kanavos, et al., 2011). This can be used to argue for the effectiveness of the 
distribution system, as the low margins may appear to drive optimizing the supply 
and warehousing. At the same time, one can also argue that more effective processes 
and operating models would drive higher margins. Some wholesalers have even 
admitted that the low margins lead to an unhealthy market (Rapeli, 2007). 
The difference from the norm in the EU is also that in Finland, wholesale margins 
are not regulated (Kanavos, et al., 2011). Whereas the reference prices of those 
medicines that are subsidized through social insurance are regulated, the wholesale 
prices are negotiated between the wholesaler and the pharmaceutical manufacturer 
case by case (Apteekkariliitto, 2020). Because the margins remain low for 
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medicines, wholesalers seek better profits from other welfare product categories 
(Rapeli, 2007). 
It should be noted that despite the one-channel system, Finland is not immune to 
disruptions or shortages in global supply chains. For example, as at the time of 
writing this thesis, the world was undergoing the COVID-19 pandemic, and 
wholesalers were not able to fulfill the increased demand for certain medical items, 
such as respirator masks (Kauhanen, 2020). Since the wholesale sector was not able 
to adapt to the situation, uncommon supply sources were utilized with poor results 
(Sutinen, 2020). Particularly, the lack of visibility of the distribution channels and 
product quality caused challenges. Whereas managing those aspects should be 
among the core competencies of medicine wholesalers, they seemed to struggle to 
react promptly. 
Considering the shortage problem, there can be multiple reasons – a global 
pandemic or similar disruption is only one potential source. For example, the WHO 
(2015c) suggests that funding mechanisms and incentives have a role to play. If 
prices for certain medicines are reduced, the manufacturer ceases to be incentivized 
to continue producing adequate amounts. Similarly, regulatory processes may slow 
down or hinder certain medicines from entering the market. What is, however, clear 
is that there is no upcoming demand visibility. There is also insufficient consistent 
data to enable proper management and supply chain visibility. Iyengar, et al. (2016) 
noted that efforts to manage medicine shortages should begin by laying a proper 
information foundation for the medicine supply chain. This is evident, considering 
that the reason for the disruption has been identified in only half of the cases 
(Azghandi, et al., 2018). 
Means to manage shortages in the supply chain have been introduced – for 
example, those relating to inventory management (such as safety stocks) and 
multisourcing strategies, as well as simulating various scenarios to find an optimal 
policy (Azghandi, et al., 2018). However, it can be argued that data transparency is 
the key (Dai, et al., 2020). This refers explicitly to suppliers disclosing information 
on their capacity levels, which are currently hidden. 
With respect to regulations in Finland, the pharmaceutical industry and 
wholesalers are responsible for importing medicines, and wholesalers for 
maintaining interim stocks and for distribution (Sosiaali- ja terveysministeriö, 2011). 
Pharmacies, hospital pharmacies and dispensaries dispense medicines to patients. 
Dispensaries are authorized medicine distribution services maintained by healthcare 
service providers, public or private (Fimea, 2018b). Hospital pharmacies, as the 
name implies, are located in larger healthcare units. Table 1 summarizes the 
medicine supply chain structure in Finland at the time of writing (Apteekkariliitto, 
2017; Fimea, 2018b, 2019a, 2019b, 2019c). 
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Table 1. Medicine supply chain in Finland. 
SUPPLY CHAIN PARTICIPANT NUMBER 
Pharmaceutical manufacturer 34 
Wholesaler 102 
Wholesaler with warehousing 2 
Pharmacy 812 




 Whereas the medicine supply chain is usually highly regulated, whereby 
authorities grant permits to operate in the market, many European countries have 
recently deregulated the pharmacy sector, which has increased vertical integration 
within the supply chain (Fimea, 2017). Vertical integration refers to the merging of 
various levels of supply chain under the same actors – for example, wholesalers 
acquiring pharmacies. Horizontal integration is another trend; it denotes the 
consolidation of the market, such as the pharmaceutical market, under few chains 
(Kanavos, et al., 2011). 
Whereas the medicine supply chain’s major role is to make medicines available 
for patients, it should be noted that not all medicines are consumed as planned. Those 
not consumed constitute waste – for example, in the UK, the annual cost of 
prescription medicine waste is estimated at GBP 300 million (Hazell & Robson, 
2015). Medicine waste is often hazardous and presents health and environmental 
risks; therefore, it needs to be treated with appropriate means (WHO, 2015a). This 
is an important standpoint in the medicine’s journey from the manufacturing plant 
to downstream markets. 
It is noteworthy that medicine supply intertwines with the wider healthcare 
supply chain and is part of the overall care delivery process (Sosiaali- ja 
terveysministeriö, 2011). In the same vein, it can be argued that the medicine supply 
chain also includes other parties, such as physicians: prescription drugs can be 
prescribed only by accredited professionals, and therefore, physicians can be 
understood as an inherent part of the supply chain. Increasing the granularity at this 
end, specific solutions and technologies used within the supply chain can be found, 
including automatic dispensing machines and ePrescription. ePrescription is a key 
solution integrating the downstream parties of the supply chain. Another view is that 
of regulators – the field is tightly regulated, and there are various policies in place, 
including generic substitution and reference price systems. In the next sections, these 
key concepts are presented in more detail. 
The medicine supply arena has been sparsely researched from the IS viewpoint; 
however, some studies can be identified. For example, Clauson et al. (2018) 
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suggested that blockchain can play a role in health supply chain management to 
prevent counterfeit products from entering markets. The other area could be health-
related devices, with a focus on investigating how the origin of a product can be 
verified. Ângelo, et al. (2017) discussed how IS can be utilized in the electronic 
labeling of medicinal compounds in the related supply chain. The researchers 
conceptualized an entire ecosystem that increases knowledge on medicinal products 
and facilitates the cross-supply between pharmacies. The researchers also argued that 
IS-related studies in this area are scarce. Another viewpoint is that of a single firm 
operating in the supply chain. Mogdil and Sharma (2017) argued that IS have an 
impact on the operational performance of a firm in the pharmaceutical supply chain. 
This happens through improving supply chain practices, which is achieved with IS. 
Based on the above, a model of the medicine supply chain is introduced 
(Figure 3). The model depicts key actors in the supply chain, including the 
pharmaceutical industry and its suppliers, wholesalers, dispensers (i.e. pharmacies 
and healthcare units, such as hospitals) and waste disposal facilities, where unused 
medicines end up. All through the supply chain, logistics is needed to deliver 
medicines. The model also includes prescribers (i.e. doctors) and patients – as they 
are, undoubtedly, key actors in the medicine supply. There are other important roles, 
such as regulators and insurers, but these are not included in this model to maintain 
a reasonable scope. Furthermore, it can be argued that the supply chain model should 
focus on concrete medicine flows (e.g. (Imran, et al., 2017)). Actors such as 
regulators are stakeholders in the related integrated health system, and whereas they 
undoubtedly influence the process, they do not actively participate in it. This thesis 
particularly focused on researching how medicines are brought to patients at an 










Figure 3. Medicine supply chain. 
Setting the Scene – Previous Literature Review and Conceptual Framework 
 27 
2.3 ePrescription 
ePrescription has been widely studied in different accounts (Abramson, et al., 2011) 
(Caldwell & Power, 2011) (Clyne, et al., 2012) (Johnson & Lehmann, 2013) 
(Salmivalli, 2008). The reported key benefits particularly relate to improved risk 
management and reduced medication errors, as pharmacies or others dispensing 
medicines do not need to try to interpret handwritten scribbles anymore. Improved 
communication between pharmacies and prescribers can reduce medication costs, 
especially for patients with multiple prescriptions (Lizano-Díez, et al., 2014). 
eHealth Initiative defines ePrescription as “the use of computing devices to enter, 
modify, review, and output or communicate drug prescriptions” (2004, p. 7). 
Whereas this definition reduces ePrescription to a digitized version of a paper 
prescription, ePrescription can also be understood as a wider concept that connects 
prescribers, pharmacies and insurers (Aanestad, et al., 2017a). For example, in 
Finland, the concept is based on a central service – Kanta, which is interfaced by 
citizens, prescribers and pharmacies (Kansallinen Terveysarkisto, 2020). Kanta 
hosts databases for personal health records, prescriptions (Prescription Centre), 
medicine information and medical certificates. 
According to Aanestad et al. (2017a, p. 16), ePrescription infrastructure 
comprises three parts: 
• eCapture: the functionality to capture the prescription. 
• eTransfer: the associated information flows to share the prescription 
between required stakeholders. 
• eDispensing: the functionality to capture the actual dispensing of 
medicines. 
What is missing from this definition is the integrative component, such as a 
centralized database, that links the different parts. (One could also argue that a 
medicine information database is a key part of such architecture.) Nevertheless, from 
the medicine supply chain perspective, this wider definition of ePrescription is key, 
as it integrates various stakeholders in the supply chain. ePrescription is considered 
a factor transforming healthcare delivery, and many governments are trusting it will 
enable better healthcare spending control through increased visibility (Aanestad, et 
al., 2017a). 
One of the key benefits of this type of comprehensive ePrescription system is the 
management of the overall medication of a patient. Traditionally, the information 
may have been dispersed across multiple healthcare service providers, but this can 
be overcome by a centralized ePrescription system (Kauppinen, et al., 2017). This 
type of wide-scale ePrescription system is, however, only available in a few EU 
countries – in 2017, these were Denmark, Sweden, Estonia, Iceland and Finland 
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(Kauppinen, et al., 2017). It should be noted that these are relatively small nations 
by population, and for example, in Finland, there is a long tradition of centralized 
and governmentally managed databases. There is also a unique social security 
identifier for each citizen – which, one can argue, paves the way for a national 
centralized database such as ePrescription. 
It is self-evident that ePrescription is just one element in a bigger puzzle related 
to the overall management of medication. ePrescription needs to be linked to 
electronic patient records of a given patient to obtain the full picture of a patient and 
their medication history. This is, technically and sociotechnically, a much wider 
concept. For example, the ownership of this data has been debated, and rather than 
running a centralized database, distributed solutions have been suggested. This 
discussion, however, is out of the scope of this thesis. 
 Figure 4 illustrates the ePrescription domain within the medicine supply chain. 
ePrescription particularly integrates the downstream arena of the chain, where 
prescribers, dispensers and patients operate. 
 
Figure 4. ePrescription in the medicine supply chain. 
 Typically, ePrescription deployments are lengthy projects in which existing 
information infrastructures, such as IS used by healthcare service providers and 
pharmacies, must be considered (Hanseth & Bygstad, 2017). An example of this is 
from Finland, where the Finnish healthcare and pharmacy sector went through the 
deployment of ePrescription in the period 2012–2016 (Mäkinen, Rautava, 
Forsström, & Äärimaa, 2011) (Kansallinen Terveysarkisto, 2020). The adoption and 
use of ePrescription was enforced through legislation (Laki sähköisestä 
lääkemääräyksestä [Electronic Prescription Act] 61/2007). The Finnish Patient Data 
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Repository (Kanta) is a database containing personal healthcare records (including 
prescriptions, however in a separate partition) collected from healthcare service 
providers’ patient IS (Kansallinen Terveysarkisto, 2021). The first steps in the 
development project were taken in 2001, so it has been a lengthy project 
(Jormanainen, et al., 2018). However, it is estimated that the annual productivity 
gains amount to EUR 50 million through saving time used for the manual processing 
of prescriptions (Parviainen, Kääriäinen, Honkatukia, & Federley, 2017). 
2.4 Prescription adherence and automatic 
dispensing solutions 
The WHO defines adherence as “the extent to which a person’s behaviour – taking 
medication, following a diet, and/or executing lifestyle changes – corresponds with 
agreed recommendations from a health care provider” (WHO, 2003, p. 3). 
Adherence is one of the key concepts in medicine delivery; nonadherence (i.e. failing 
to follow prescribed treatment) may lead to adverse effects and, ultimately, increased 
mortality (Chisholm-Burns & Spivey, 2012). Nonadherence is costly as well – as it 
leads to an increased need for health services, such as outpatient visits or inpatient 
treatment (Kane & Shaya, 2008). For example, in the US, nonadherence costs 
USD 300 billion every year (Foo, et al., 2011). This is not surprising, given that 
according to WHO’s estimates, adherence is typically at 50% among patients with 
chronic conditions (WHO, 2003) – in other words, only half of patients actually 
follow prescriptions. 
The reason for non-adherence can be intentional or unintentional, whereby the 
patient may either actively or passively discard the prescription (Gadkari & 
McHorney, 2012). Passive, unintentional nonadherence can be about forgetting to 
take the dose at the right time. Particularly, those with polypharmacy (i.e. having 
multiple medications at the same time) are in the danger zone (Marcum & Gellad, 
2012). These are often elderly people with lowered cognition capabilities, which 
worsen the problem. According to Sorensen et al. (2005), problems are caused by a 
large number of prescribers and dispensers for medications found in the home, 
hoarding, multiple storage locations for medication, the lack of medication 
administration routines, discontinued medication repeats retained and a mix-up of 
names of medicines. 
Often, however, nonadherence is intentional, whereby the patient actively 
decides not to comply with the prescription. This can be due to the patient’s beliefs 
in terms of the treatment and their condition (Gadkari & McHorney, 2012). In fact, 
it has been suggested that the so-called unintentional nonadherence is not completely 
passive; rather, beliefs about medicines may steer toward nonadherent behaviors 
such as forgetfulness (Unni & Farris, 2011). 
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In any case, interventions are required to tackle the issues. Various solutions 
have been proposed – for example, ingestible biosensors emitting a radiofrequency 
signal when encountering a certain pH value (Chai, et al., 2016), electronic pillboxes 
(Hayes, et al., 2006), blister packaging (Connor, et al., 2004) and phone reminders 
(Unni & Farris, 2011). One of the key solutions is, however, the automatic medicine 
dispenser. Automatic dispensers were introduced in the 1960s to offload the 
medicine administration burden from nurses (Balka, et al., 2007). Modern automatic 
dispensers intend to provide an end-to-end solution, with functionality spanning 
from the physician order entry to the sorting of medicines and distribution to either 
nursing staff or patients. 
Typically, medicines come out from the automatic dispensers in plastic packs, 
guiding and facilitating that the right dose is taken at the right time (Van Den Bemt, 
et al., 2009). A common type is blister packaging, which is illustrated as Exhibit A 
in Figure 5; however, other types exist, such as strip packing, which is based on heat-
sealable coated films, and aluminum foil packaging (Choundary, 2015). In blister 
packs, medicines are sorted and packed in separate blisters in the order they should 
be consumed. Some also prefer pouches and sachets (Exhibit B in Figure 5), which 
contain one or multiple medications that need to be consumed at the same time 
(Clews, 2017). The traditional manual pill dispenser is also illustrated in Figure 5 as 
Exhibit C. 
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Figure 5. Different medicine packaging types (A: https://commons.wikimedia.org/wiki/File: 
Pharmaceutical_Blister_Pack.png, B: https://www.pxfuel.com/, C: https://www.piqsels.com/). 
 Automating the dispensing process can reduce medication errors relating to 
medicine administration; this is common sense, as a robot will not make the so-called 
human errors. Furthermore, automatic dispensing can contribute to adherence, as 
medicines become available at the right time. Some automatic dispensers are 
connected devices with functionality to notify in case of deviations, and this way 
further tackles the adherence problem (Suomi, et al., 2016). In addition to enforcing 
adherence, dispensers are also commonly understood to facilitate efficiencies, as 
they reduce the administrative burden and remove manual tasks in the medicine 
delivery process. 
From the medicine supply chain perspective, automatic dispensing integrates 
actors in the downstream. One related service is automated dose dispensing (ADD). 
ADD connects the pharmacy, physicians and caregivers: prescriptions are sent from 
a pharmacy to ADD service providers – who package medicines according to the 
prescription (taking into account doses, dispensing times and so forth), which are 
then inserted into automatic dispensers (Suomi, et al., 2016). 
There are also critics of automatic dispensers. For example, in some cases, they 
can increase the risk of a medication error. If, for instance, the dispensed medicine 
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requires additional manipulation, such as crushing, this typically remains a manual 
task, which is error-prone (Van Den Bemt, et al., 2009). 
The reasons for nonadoption have been studied in Finland, and they include costs 
and regulations (Suomi & Li, 2014). Dispensers are typically expensive, and they 
are not fully covered as part of standard health plans. Dispensers also need to 
incorporate failsafes and assurance mechanisms, which makes them expensive to 
build. Regulations also hinder adoption since the fulfillment and validation process 
requires pharmacy visits. Figure 6 depicts which parts of the medicine delivery chain 
automatic dispensing covers. 
 
Figure 6. Automatic dispensing in the medicine supply chain. 
2.5 Regulatory perspective 
The area of medication is highly regulated. For example, it is commonly regulated 
that only accredited professionals can prescribe medicines. Moreover, it is regulated 
that only accredited pharmacies can dispense these medicines and that the 
development and manufacturing of medicines must follow strict guidelines. 
Separating prescription and dispensing originates from medieval times when states 
began to seek to regulate this and forbid a single party from diagnosing and 
dispensing (Liaw & Peterson, 2009). However, there are differences between regions 
on how strict these regulations are. 
The introduction of regulated prescriptions dates to the 1930s (Flanigan, 2012). 
Not all countries are, however, enforcing strict prescription laws. Particularly in low- 
and middle-income countries, it is typical that pharmacies act as the first and only 
interface to health services for many, and pharmacies dispense medicines without 
requiring a prescription (Abdelaziz, et al., 2019). Whereas one can argue that this 
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may contribute to the misuse of medicines such as antibiotics, leading to more 
resistant bacteria, many do not have access to a physician and need to rely on 
pharmacists and self-medication. There are also ethical questions regarding whether 
the prescription system is violating one’s right to self-medicate and is a manifestation 
of paternalism (Flanigan, 2012). 
The right to prescribe medication in Finland is regulated so that only physicians, 
dentists and nurses who are specifically authorized to prescribe certain medicines are 
entitled to prescribe medication to patients (Sosiaali- ja terveysministeriön asetus 
lääkkeen määräämisestä [Decree on medicine prescribing] 2010/1088). After the 
prescription is made and the patient fetches it from a pharmacy, another regulatory 
tool comes to play: the generic substitution system. 
The purpose of generic substitution is to replace higher-priced brand products 
with lower-priced generic products. In Finland, for example, pharmacies are 
mandated to substitute brand-based prescriptions with generic products if a generic 
equivalent is available and it is at a lower price (Lääkelaki [Medicines Act] 
395/1987). The equivalent product needs to, of course, contain the same active 
ingredients as the brand product. 
The generic substitution system is a key mechanism in managing medicine costs, 
whether paid for out of pocket by consumers or subsidized by the state. As 
supporting evidence, in Finland, medicine expenditure slowed after the introduction 
of generic substitution in the 2000s (Fimea and Kela, 2015). There are, however, 
countries regulating less in this area – for example, in the US, the lack of generic 
substitution is estimated to cost USD 9 billion annually in outpatient care (Stenner, 
et al., 2010). 
Another related regulatory component is the reference price system, which 
mandates prices for medicines in a jurisdiction. In Finland, this is built into the 
legislation (Lääkelaki [Medicines Act] 395/1987). Countries negotiate the prices 
individually for various medicines with related pharmaceutical manufacturers and 
typically utilize some benchmarking pricing information from similar countries 
(Kalo, et al., 2013). 
The pharmaceutical defines an ex-factory price for a medicine, which is used as 
a basis for price negotiations. The ex-factory prices are different, depending on the 
market, and therefore, the reference prices can differ by country. It is also suggested 
that new medicines become available to higher-income countries with higher price 
levels (Vogler, et al., 2019). It is suggested that ex-factory prices are relatively low 
in Finland (Kanavos, et al., 2011). 
Each wholesaler in Finland negotiates the purchase price for medicines it 
distributes (Apteekkariliitto, 2020). The reference prices for wholesale prices are 
regulated by the Pharmaceutical Pricing Board for those medicines that are 
reimbursable through social insurance and are included in the generic substitution 
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system (Pharmaceutical Pricing Board, 2020). The board defines reference price 
groups, wherein similar medicines (i.e. medicinal products with the same active 
ingredients, dosages and package sizes) are grouped, and determines a reference 
price for the given group. Pharmaceutical companies then confirm their wholesale 
prices, which cannot exceed the reference prices. Reference prices are valid for 
three-month periods, and wholesalers are required to notify the new wholesale prices 
before the beginning of each period. (Pharmaceutical Pricing Board, 2020) 
The retail price of a prescription medicine in Finland is the sum of the wholesale 
price – which, if applicable, can be up to the reference price – the pharmacy margin 
and 10% value-added tax (Apteekkariliitto, 2020). The pharmacy margin is regulated 
by law in Finland, and it depends on the wholesale price of the medicine; the more 
expensive the wholesale price, the lesser the margin (Valtioneuvoston asetus 
lääketaksasta [Decree on drug tariffs] 713/2013, 2013). 
The combination of generic substitution and reference pricing systems is an 
effective mechanism to manage medicine costs. From the pharmaceutical industry 
point of view, this is, however, challenging, as pharmaceutical manufacturers need 
to maintain the profitability of the business. Investments required to develop a new 
medicine are often counted in billions; should the profits decrease, there may be less 
investments in pharmaceutical research and development. Another implication could 
be that the ex-factory prices are raised, making medicines less accessible in lower-
income jurisdictions (Kalo, et al., 2013). This requires careful balancing from the 
regulator, as new medicines can lower healthcare costs and even mortality rates. 
However, the prices of medicines are typically high, and the market needs to be 
adequately attractive for the pharmaceutical industry to invest. 
Another noteworthy policy topic is copayment, which is another instrument for 
managing medicine costs. Potential policies include cap policies, whereby the 
amount of prescriptions (which is reimbursed to the patient through, for example, 
social insurance) is restricted (i.e. capped); ceiling policies, whereby the reimbursed 
fees are restricted to certain amounts; and coinsurance, whereby the patient covers a 
certain part and the insurer the remaining part (Luiza, et al., 2015). For example, in 
Finland, prescription medicines are reimbursed, after an initial EUR 50 fee, at 40%, 
65% or 100%, depending on the medicine (KELA, 2020). There is also a cap for out-
of-pocket costs; if the cap is met, an additional reimbursement is introduced (KELA, 
2020). 
It has been shown that changes to the reimbursement rates of a medicine have an 
impact on the consumption of that particular medicine (Garcia-Gomez, et al., 2018). 
This has been reported to have varying implications. Introducing copayment and cap 
policies may have adverse health and economic effects since medicines prescribed 
for chronic conditions, for example, may become less available for those who need 
them (Luiza, et al., 2015). This may increase the need for treatment and hospital 
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stays. Conversely, it has also been reported that introducing even a minor, nominal 
payment reduces consumption (Garcia-Gomez, et al., 2018). This may have a 
positive impact if the reduced consumption is due to reconsidering the given 
prescription with a relevant professional. 
There are regulations to protect the industry as well. It is particularly the 
counterfeiting that regulators are trying to curb through new legislation. Currently, 
intellectual property relating to pharmaceutical products can be protected with 
patents. The World Trade Organization requires a 20-year protection period, which 
has been mandated under the Trade-Related Aspects of Intellectual Property Rights 
Agreement (WHO, 2021). However, the medicine counterfeit market is estimated to 
have risen to USD 200 billion, and it is clearly a global issue (Janvier, et al., 2018). 
The EU defines two types of counterfeiting: First, a falsified medicine is made to 
resemble the original product but may not contain the right active ingredients 
(European Medicines Agency, 2018a). Second, counterfeit medicines are those 
breaching intellectual property rights – that is, made using a patented formula 
without a license. 
To stop counterfeiting, the EU has introduced multiple regulatory measures. 
These include a two-dimensional barcode and an antitampering device in the 
medicine package, which have been mandatory for prescription medicines and some 
OTC medicines as of the first part of 2019 (European Medicines Agency, 2018a). 
The pharmaceutical manufacturer is required to upload the unique identifier, 
reflected by the barcode, to a centrally managed EU database, which is then queried 
in the different phases of the supply chain to verify the authenticity of the medicine.  
Good Distribution Practice requires supply chain parties, such as wholesalers, to 
verify the incoming consignments (Guidelines on Good Distribution Practice of 
medicinal products for human use, 2013). The EU’s Good Manufacturing Practice 
governs the manufacturing process itself, stipulating that any suppliers used to 
provide, for example, raw materials and ingredients are of an adequate standard 
(Standard l) (European Medicines Agency, 2018b). 
Similar initiatives have been launched in the US. The FDA introduced the Drug 
Supply Chain Security Act in 2013 (FDA, 2018a). The act mandates the traceability 
of medicines through the supply chain as well; however, it is less prescriptive and 
not based on a centralized state-led database. Nevertheless, it mandates serialization 
of medicine packages and traceability across the supply chain. Other jurisdictions 
are taking similar actions to stop counterfeiting (e.g. (Tseng, et al., 2018)). 
Turning attention to the end of the supply chain model – that is, waste disposal 
– this area is varyingly regulated around the globe. This topic is discussed in 
Section 2.6. 
The key regulations and their domains in the supply chain are depicted in 
Figure 7. It should be noted that there are also many other regulations in the area of 
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medication and healthcare, such as those relating to the clinical testing or the 
marketing of medicines. Further discussion on those areas in this thesis is omitted 
for the sake of brevity and considering the focus on the supply chain. 
 
Figure 7. Some central regulations across the medicine supply chain. 
2.6 Medicine waste disposal 
Medicine waste disposal can be approached from two perspectives: first, how it is 
carried out in institutions, such as hospitals, and second, how it is conducted in 
households and homes. Medicine waste comprises unused, expired and 
contaminated medicines. It is part of healthcare waste, which also covers other types 
of waste generated in the course of healthcare delivery, such as pathological waste 
and syringes (WHO, 2015a). Furthermore, consumed medicines can be argued to 
generate waste; this is simply because consumed medicines tend to end up in the 
public sewage system through natural ways (Rogowska, et al., 2019). 
Medicine waste can cause many problems if not properly processed. For 
example, it can contaminate drinking water and, therefore, cause health problems 
(WHO, 2015a). Unprocessed medicine waste from landfills can be propagated to 
ground water – for example, in Germany 156 pharmaceuticals were detected in 
drinking water (Kuster & Adler, 2014). Furthermore, it has been shown that water 
treatment plants are unable to filter all the pharmaceutical waste from sewage 
wastewater (Rogowska, et al., 2019). 
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The environmental risk is acknowledged, and there have been attempts to 
regulate it. For example, in the US, the arena is heavily regulated through the 
Medical Waste Tracking Act, which governs the collection and processing of 
medical waste (Winfield & Brooks, 2015). Medical waste here refers particularly to 
that generated by healthcare facilities, rather than households (U.S. Environmental 
Protection Agency [EPA], 2017). 
The EU has established the Directory of Hazardous Waste, which is mandated 
for each member country (Winfield & Brooks, 2015). The issue, however, is that it 
is only a directive rather than actual legislation, leaving leeway for interpretation and 
adoption across the union. This is a global issue: there is no unified definition for 
medical waste, although it is evidently a significant health and environment hazard. 
Furthermore, the aforementioned regulations govern medicine disposal in 
healthcare units only. A lot of waste is also generated in households. According to 
Finnish legislation, municipalities are responsible for arranging waste collection for 
households – including hazardous waste, such as medicine waste (Jätelaki [Waste 
Act] 646/2011, 2011). Finnish municipalities tend to do this without charge in order 
to attract citizens to dispose of hazardous waste in a proper way (Suomen Kuntaliitto 
ry, Suomen Kiertovoima ry [KIVO] & Suomen Apteekkariliitto ry, 2019). 
In Finland, the disposal of medicine waste is carried out through pharmacies, 
where people can return their unused medicines and other medicine waste without 
cost. Municipalities have agreed to this arrangement with the Association of Finnish 
Pharmacies (Suomen Kuntaliitto ry, Suomen Kiertovoima ry [KIVO] & Suomen 
Apteekkariliitto ry, 2019). The role of the pharmacy in the medicine waste disposal 
process is not peculiar only to Finland; many other European countries have a similar 
system whereby pharmacies accept unused medicines from households (Rogowska, 
et al., 2019). EU Directives 2001/83/EC and 2001/82/EC mandate member countries 
to arrange for the collection of expired medicines (Rogowska, et al., 2019). Again, 
since this is a directive, it leaves room for each of the member countries to interpret 
and implement it as it wishes. 
The extent of household medicine waste should not be underestimated. Many 
medicines are available without prescription, and they contribute to the increasing 
wastage. For example, the consumption of ibuprofen, a common pain reliever, 
amounted to 975 tons in Germany in 2012, whereas it was 250 tons in 2002 (Kuster 
& Adler, 2014). It is common sense that this will have consequences for the 
environment. 
Medicine waste from pharmacies and healthcare units is usually incinerated. 
Other methods include autoclaving and microwaving (Messerle, et al., 2018). For 
example, in Finland, the waste disposal plant processes 400 tons of medicine waste 
annually (Hyvönen, 2016). Medicine waste is delivered to the plant in large 
containers, which are incinerated at a high temperature. The incineration temperature 
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is usually between 900°C–1200°C. Whereas this certainly disinfects the medical 
waste, it may release hazardous substances such as dioxins into the environment 
(Messerle, et al., 2018). The bottom ash may also remain toxic (Hossain, et al., 
2012). The problem is also more significant in developing countries, which may lack 
relevant regulatory and waste disposal mechanisms. 
To conclude this section, one more viewpoint is introduced. In this thesis, the 
medicine supply chain is discussed from the perspective of human medicines. 
However, livestock are medicated as well, and their manure is used for fertilization, 
releasing more medicines to the environment. All effects of the pharmaceutical 
exposure to the environment, people, livestock and wildlife are yet to be seen 
(Arnold, et al., 2014). 
 
3 Theoretical Foundation 
3.1 Summary of theoretical background in this 
thesis 
This thesis draws from information asymmetry theory, and it is used to explain 
bottlenecks in a given domain. In terms of related articles, Article I specifically refers 
to this theory in the course of building the initial model for this thesis. The scarce 
and unequal information is revisited in the following articles. 
Furthermore, the sociotechnical systems model is utilized when examining the 
transformation in the domain, as well as inefficiencies across the medicine supply 
area. Article II views the transformation in the pharmacy sector through this 
theoretical lens. Article III utilizes the model as well when examining the 
management of medicine waste in a hospital. In this chapter, these two theories and 
their applicability in the healthcare and medicine supply arenas are discussed. 
3.2 Information asymmetry 
3.2.1 Information asymmetry as a concept in the healthcare 
and pharmaceutical markets 
The healthcare market is pervaded by unequal information. In this thesis, a model of 
the medicine supply chain has been introduced, and it will be demonstrated that there 
are multiple disconnections between the various actors, leaving the entire ecosystem 
across the supply chain to operate largely in the dark. 
If attention is turned to the healthcare market as a wider concept, expanding the 
discussion in Section 1.2, the consideration can begin with the physician-patient 
relationship. As described by Arrow (1963), the asymmetry derives from the fact 
that physicians are accredited professionals with years’ worth of education, usually 
having a deep understanding and knowledge of their field. Conversely, patients are 
often laymen without extensive knowledge of treatments or the capability to evaluate 
recommendations they receive from healthcare professionals. By default, patients do 
not understand the economic impact of their treatment, either. 
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The consequences can be severe, especially for patients with polypharmacy (i.e. 
those with multiple medications). The risks relating to polypharmacy include ADRs, 
increased hospital stays and mortality (Masnoon, et al., 2017). The situation becomes 
especially risky when there are multiple prescribers without visibility to all 
prescriptions. One way to mitigate this is through making adequate information 
available with ePrescription and electronic health record systems, which intend to 
maintain a unified view of the medication regimen for the given patient. (Please see 
Section 2.3 for more discussion on this.) 
One of the implications of information asymmetry is the moral hazard. This 
occurs when party A must bear the risk for party B’s actions but has no means to 
control party B’s intentions or how they behave. Party B then exploits this 
information asymmetry and transfers the risk to party A. This is typically an issue in 
the insurance industry, whereby the insurer cannot evaluate how the insured acts or 
manages the risk after the insurance agreement has been signed (Arrow, 1963). 
In the context of medication, nonadherence is susceptible to moral hazard. This 
is especially true if the patient does not directly cover the cost themselves but it is 
covered by an insurance arrangement. This drives increased insurance fees, and in 
the case of national health insurance taxpayers, the patient eventually bears the cost. 
It should be noted that an asymmetric position as such is not a problem directly. 
Actually, it is a norm in business: firms have confidential information they use to 
gain a competitive edge, people have their personal data they want to keep to 
themselves, and so on. This inequality can have adverse effects on the market; 
however, when exploitation goes too far – as was proven by Akerlof (1970), who 
studied the used cars market (which later made him a Nobel Laureate). He showed 
that car sellers selling the so-called lemons (i.e. cars in poor condition) while hiding 
information about the defects eventually led to market failure. As buyers usually 
have no means to verify the condition, defective cars can be sold at the same price 
as nondefective cars. This leads to better cars disappearing from the market, leaving 
only defective cars (i.e. lemons), which eventually erodes the trust from the market. 
This is also called adverse selection. 
The healthcare and medicine supply markets are prone to similar failures and are 
therefore protected through strict regulations. A failure would have grave 
consequences and could entail higher mortality. For example, if falsified or 
contaminated medicines were propagated to the market and people could not trust 
the medicine dispensed in the pharmacy is what it is supposed to be, and, therefore, 
cease to consume prescribed medicines, the entire basis for the healthcare system 
would collapse. This is, of course, an unlikely scenario in the developed world, 
where medicine supply is highly regulated. In markets where regulations are less 
developed, however, this can be a real risk. In many emerging regions where 
healthcare services are scarcely available, pharmacies are the first and perhaps only 
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channel for treatment. According to the WHO, one in 10 medicines is falsified or 
otherwise substandard in low- and middle-income countries (WHO, 2017). 
It is especially generic products that are susceptible to falsification since there 
may not be adequate testing facilities and policies to verify that the given generic 
medicine contains the required active ingredients (Silverman & Glassman, 2019). 
This leads people to avoid the generic products and choose the brand product; it is 
the market of generic medicines that fails in this case. As described in this thesis, 
generic substitution is a critical element to manage medicine expenses and 
contributes to a sustainable healthcare system. Information asymmetry is a 
particularly problematic situation for most vulnerable people in the world. 
Some authors have even further suggested that the entire medicine market is 
largely a lemon market. Light and Lexchin (2021) discussed how new medicines are 
developed and marketed as superior to existing medicines; however, if risks such as 
ADRs are weighed, the benefit is questionable. According to the authors, there are 
multiple layers of mechanisms smoke screening those with lesser information, 
including unreliable clinical trials, biased scientific literature and hidden adverse 
effects. The authors back their findings through presenting several statistics on how 
ADRs have increased over the past few decades. The difference to Akerlof’s (1970) 
used cars market is that new lemon medicines cost more and there is no trend for 
lower price levels in the market. 
3.2.2 Uncertainty and information asymmetry as a supply 
chain problem 
Whereas the patient-centered downstream is usually emphasized, information 
asymmetries also exist in other parts of the medicine supply chain. One example is 
pricing information: it can be considered a normal business practice to hide pricing 
information between markets. Pharmaceutical manufacturers negotiate prices with 
each country and do not disclose information widely on their ex-factory prices 
(Vogler, et al., 2019). Another example relates to shortages: information on 
disruptions have not been adequately available from pharmaceutical manufacturers 
(Rees, 2020). This information asymmetry, whether due to the upstream actors 
hiding information on disruptions or due to a general lack of transparency, can be 
understood as one of the root causes for medicine shortages. Given the disruption 
would be known earlier, precautionary actions such as ordering a substitute medicine 
could be taken. 
Global supply chains may have single points of failures that are not fully 
understood in the downstream, and downstream parties are left to react to sudden 




To manage medicine shortages, an EU regulation for mandating pharmaceuticals 
to submit information on supply disruptions is underway (Rees, 2020). This has been 
accelerated by the COVID-19 pandemic. Finnish law already requires the importer, 
as well as the wholesaler, to inform authorities in case of a disruption (Laki lääkelain 
muuttamisesta [Amendment to Medicines Act] 553/2020). 
Sometimes no supply chain party deliberately hides information, but rather the 
signals are not collected and interpreted. Data that could reveal an upcoming 
disruption might be available through various datasets, news feeds and such, but 
those are not utilized. Again, in the context of medicine supply, if the supply chain 
is not fully understood, transparency is not demanded or created, and predictive 
models creating more information are not developed. Those who do it gain a more 
powerful position, as they can prepare for disruptions and recover from those faster. 
At higher levels, these kind of information asymmetries could exist between 
competing countries and regions. Overall, considering medicine supply, the focus 
should be aimed at the upstream when considering the data, and data are often the 
key when creating or removing information asymmetries – it is clear that those who 
master it benefit. 
3.2.3 Patient empowerment as a concept to manage 
information asymmetries and incomplete information 
The information asymmetry between the physician and patient exists the other way 
around as well; one example is prescription nonadherence. A patient may choose to 
not follow a prescription and hide information on this. To tackle this, the options 
include monitoring and enforcing adherence. There are ways to do this, such as using 
automatic dispensers; however, this may be problematic from, for example, the 
privacy viewpoint. Patient empowerment, however, is suggested to be a cost-
efficient and ethical means to manage the moral hazard. 
Patient empowerment can be defined as “patient management that, through 
health education and the promotion of health-friendly behaviors, provides the person 
with the critical tools to make better decisions for their well-being, reducing cultural 
and social inequalities” (Ippolito, et al., 2019, p. 93). It is often the patient themselves 
who is the best expert in their condition, as they are the one experiencing it. 
Patient empowerment can be understood as an instrument to manage the 
information asymmetry inherent in the healthcare market. The empowerment is both 
a process and an outcome in such that it entails actions required to enable a patient 
to take better control of their treatment – which, as the outcome, results in better 
understanding regarding own well-being and therefore better health results (Ippolito, 
et al., 2019). This is beneficial not just in terms of individuals’ rights and self-
efficacy but also from the cost perspective. 
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Self-management is particularly important in terms of chronic conditions, 
whereby treatment is a lengthy and continuous process (Ippolito, et al., 2019). If the 
patient misses the treatment, the condition may worsen and require more treatment. 
This, of course, increases costs. It is, therefore, self-evident that patient 
empowerment is an important element to manage costs with aging populations. 
Patient-physician information asymmetry is problematic since health is a personal 
and sensitive topic; introducing a monitoring framework to reduce the information 
asymmetry can be deemed surveillance and breaching one’s privacy. Patient 
empowerment is not invasive. It does not remove the asymmetry but helps to cope 
with it. 
Information as such plays a crucial role in patient empowerment, as it is based 
on information sharing and information availability (Loukanova, et al., 2007). The 
patient needs to understand their condition and the treatment, including the related 
medication. This increased information is an antecedent to the motivation required 
to better engagement with the treatment. Pharmaceutical prescription is, however, a 
problematic area, as despite the improved adherence, the patient may not be able to 
judge the effect of the prescription during or even after consumption. Hence, patient 
empowerment is not an adequate solution on its own. 
3.2.4 Regulation as a controlling tool 
Regulations are key instruments for managing information asymmetries. One 
example is generic substitution. Usually, a patient does not have the ability to assess 
prescribed treatment. To combat medicine costs, whether out of pocket or 
subsidized, the system reduces the asymmetry, as it mandates the prescription to be 
evaluated by a professional (i.e. the pharmacist) while dispensing and be replaced if 
necessary. Furthermore, separating prescribing and dispensing prevents the moral 
hazard relating to prescribers lobbying certain pharmaceutical brands or treatments 
(Liaw & Peterson, 2009). 
Another policy intervention is copayment. The reimbursement of medicine costs 
presents the risk of moral hazard, whereby the consumption of medicines is not 
considerate. It has been reported that introducing even a minor out-of-pocket cost 
for a medicine reduces its consumption (Luiza, et al., 2015) (Garcia-Gomez, et al., 
2018). Finding the right balance with copayment is a key question for medicine 
supply. The policy needs to combat the moral hazard while keeping medicines 
affordable and accessible for those who need them. 
To understand some further information asymmetries in the pharmaceutical 
market, the works of Spence (1973) and Stiglitz (1975) need to be considered. In 
addition to Akerlof, they were rewarded the Nobel Prize for Economic Sciences in 
2001 on the works they conducted on asymmetric information (Nobel Media AB, 
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2001). According to Spence’s signaling theory, actors in a market reduce information 
asymmetry through signaling the information to less-informed parties (Spence, 
1973). Conversely, Stiglitz viewed the phenomenon from the perspective of the less-
informed party and suggested they undertake screening actions to reduce asymmetry 
and adverse selection (Stiglitz, 1975). 
The regulation governing clinical trials protects consumers who cannot evaluate 
how a pharmaceutical manufacturer assures the safety of its products. In this case, 
the pharmaceutical manufacturer does not need to pay for signaling in terms of the 
safety of the product, as consumers can expect all pharmaceutical products in the 
market to have been adequately tested (this is not to say that they would not need to 
advertise to differentiate). Conversely, consumers do not need to screen products to 
find a safe one. 
In low- and middle-income countries, where regulations and testing practices are 
scarce, signaling is more important. This is where a brand product – a brand is a 
signal – may be the only option for a buyer, as they cannot trust generic products, as 
described above. 
Whereas a regulation may reduce signaling or screening costs, it has a price, as 
it typically requires heavy monitoring and enforcing. Another problem with 
regulations is that they are typically behind technological innovations (Koskinen, 
2016). This blocks innovations and causes economical inefficiency. Considering the 
clinical R&D case, the massive regulatory framework effectively blocks new 
entrants entering the market. Spence (2015) suggested that digital technologies and 
platforms in particular are changing this landscape, as they are introducing new kinds 
of trust mechanisms. Digital platforms such as AirBnB and Uber equalize 
information about buyers and sellers through user ratings, and there is no 
requirement for a third party. Fraudulent and malign actors are removed quickly from 
the platform. Noteworthy here is that the monitoring and enforcing costs are small. 
How this would work in the healthcare and medicine supply domain remains to 
be seen. The patient empowerment requires information on treatments and 
conditions to be available; however, this information must be valid to avoid, again, 
eroding trust in the market. In other respects, health is such a topic that deregulating 
seems far-fetched in terms of, for example, testing and verifying products. It is, 
however, a question how these regulations can be implemented in a cost-efficient 
manner so that emerging markets could also deploy and benefit from them. 
Another discussion is the one relating to privacy and control over own data. 
Digital technologies and technological solutions can be used to collect data in real 
time to monitor behavior. In the health insurance market, utilizing wearables and 
monitoring, for example, health records can be used to calculate personal premium 
levels. Mobile applications monitoring activity levels are already present (e.g. (Fjuul, 
2020)). This, however, is objected by many authors. For example, Zuboff (2019) 
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introduced the term surveillance capitalism, which is an economic system driven by 
personal data collected through various digital channels creating significant power 
inequality for the benefit of big businesses. Hence, whereas removing the 
information asymmetry through digital means might seem a good solution from the 
market viewpoint, it might lead to an unequal power structure. 
3.2.5 The concept of asymmetric information in this thesis 
In addition to the few examples outlined in this section, there are also many other 
asymmetries in the medicine supply. Article I identifies these asymmetries and 
investigates potential solutions, especially based on digital technologies. The article 
models the medicine delivery value chain and identifies problem areas in the chain, 
including those relating to prescribing and patient adherence. Article III also 
explores information asymmetries while reviewing the medicine delivery process in 
a hospital. In this article, it is demonstrated that incomplete and poor information is 
one of the reasons for an inefficient delivery process. 
The reason this thesis utilizes the concept of information asymmetry is that the 
intention is to identify bottlenecks in the medicine supply chain and suggest 
solutions. The medicine supply is a highly information intensive arena whereby 
incomplete or unequal information causes friction in the chain. The general thesis 
based on Article I is that reduced information asymmetry is, in fact, one of the key 
benefits of digitalization and an indicator of the wider impact of digital technologies 
and digitalization on an economy. 
Conversely, Article IV suggests a solution to manage asymmetric information 
with DLT; the article specifically discusses that actors seek to hide their critical 
business information in a competitive market. To tackle this problem, a DLT-based 
solution can be utilized to remove the need for a centralized database and reduce the 
amount of information various parties in the business network need to know about 
each other. It should be noted that hiding information may have ethical and severe 
health-related impacts, and therefore, it is important to manage it. 
Various information asymmetries across the medicine supply chain have been 




Table 2. Asymmetric information across the medicine supply chain. 
ASYMMETRIC 
PARTIES 
IMPLICATIONS LITERATURE POTENTIAL 
SOLUTION 
Physician-patient Patient less aware 
of treatments and 
their effects 
(Arrow, 1963) 




Patient-physician Patient may hide 
information on 
adherence 
(Ippolito, et al., 
2019) 
(Loukanova, et al., 
2007) 
Patient empowerment 













Solutions to monitor the 
behavior, such as 
wearables 
Pharmacy-patient Pharmacy may hide 
information on the 
most cost-effective 
treatment 





Regulations such as 







hide information on 
supply disruptions 







hide information on 
the quality and 
effectiveness of a 
medicine 
(Light & Lexchin, 
2021) 
Regulatory framework 
for clinical trials, 




3.3 Sociotechnical systems model 
The sociotechnical systems model is a widely used concept in IS research. The 
theory examines IS from the point of view of both social and technical subsystems 
(Bostrom & Heinen, 1977). The theory is based on the assumption that these 
subsystems must fit to enable the successful adoption of IS in organizations. Too 
often, the changes introduced by a new system are not understood, especially 
because technical and social variables are interdependent and the relationships are 
not resolved in the design phase (Bostrom & Heinen, 1977). This can lead to 
problems and resistance from users toward the new system. This eventually causes 
the rollout to fail – although, technically, the system would be fully viable. In fact, 
it is reported that only 10% of IS projects fail due to technical reasons, whereas 90% 
fail due to social reasons (Dohert & King, 1998). 
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The roots of the theory derive from the 1950s, when it was introduced at London 
Tavistock Institute (Mumford, 2006). The approach advocated for better working 
conditions and worker democracy in factories and coal mines. According to the 
theory, when technology becomes deterministic, task structures are built around 
them without considering people. This deteriorates working conditions, making 
them routinized, less humane and degrading. Whereas the problem was evident in 
conveyor belt assembly lines, the theory’s heyday was especially in the 1970s and 
1980s, when it was applied to office surroundings. These were the early days of 
computerization, when the rollout of new information technology profoundly 
changed working practices and task structures. This caused friction at workplaces. 
Sociotechnical systems design practices intended to combat this through 
incorporating organizational and people aspects in the design of a new system. 
Sociotechnical factors have been studied in healthcare IS research in various 
accounts (e.g. (May, et al., 2001), (Aarts, 2012)). The sociotechnical approach is 
lucrative in healthcare environments – as they are often labor-heavy and complex, 
yet dependent on IT (Coiera, 2007). However, it is not rare that a failed healthcare 
IT project is reported in the media. It seems new systems are implemented without 
considering the impact on workflow and staff, which causes chaos and disorder (e.g. 
(Allen, 2019)). Often, the new system is only partially used, and parallel shadow 
practices remain. Furthermore, health systems are different, and one size rarely fits 
all, which should be considered when integrating a new IT system. Arguably, 
sociotechnical analysis has a role to play in all this. 
Relating to the medicine supply domain, ePrescription has been especially 
studied from the sociotechnical perspective. For example, pharmacists might 
demonstrate resistance toward the new prescription system (Clauson, et al., 2011). 
ePrescription may also lead to changing jurisdictions of professionals across the 
prescription process – as pharmacists, for example, may have access to information 
that was available for only physicians before (Motulsky, et al., 2011). This may lead 
to friction between these professional groups. 
Another area of discussion is how new digital systems, such as ePrescription, 
contribute to deskilling or reskilling. According to Petrakaki et al. (2012) 
ePrescription contributes simultaneously to both. The deprofessionalization may 
occur through replacing manual processes, which required a higher degree of 
professionalism, with automated processes. A higher degree of automation 
transforms the process more piecemeal to human workers, something one can 
associate with a conveyor belt assembly work. The authors also argue that 
ePrescription can depersonalize the process leading to losing interoccupational 
personal relationships – for example, those between physicians and pharmacists. On 
the beneficial side, Petrakaki et al. (2012) argued that ePrescription can 
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reprofessionalize pharmacy staff, as automating mundane processes frees time for 
more challenging tasks. 
In another study, Petrakaki et al. (2014) discussed how ePrescription impacts the 
jurisdiction of pharmacists and pharmacy staff. According to the researchers, 
responsibilities, for example, may be displaced, leading to the jurisdiction of the 
technical pharmacy becoming wider. This may then entail blame shifting and other 
similar consequences. This may not be the original intended use of the system but 
rather a novel affordance ePrescription provides. The affordance concept changes 
the discussion about reskilling/deskilling – which has traditionally assumed a 
deterministic view to technology, whereby technology dominantly leads to reskilling 
or deskilling (Hutchby, 2001). Conversely, affordance mixes the materiality of a 
technological artifact and the social processes, whereby technology provides 
affordances (i.e. opportunities and risks) and it is up to the users to adopt those. 
Harvey, Avery, Waring and Barber (2012) studied the sociotechnical impact of 
ePrescription in community pharmacies in relation to the upcoming new release of 
the national ePrescription service in the UK. The researchers particularly 
investigated how ePrescription affects work practices and discovered that 
pharmacies can be divided into three categories based on the sociotechnical 
orientation: technically oriented, improvising and socially oriented. These categories 
are characterized by different levels of utilization of technology, dispensing process 
governance and strictness of workflow methodology. Harvey et al. (2012) found 
significant distinctions in the dispensing procedures and lead times (i.e. the time 
between accepting the prescription and dispensing it to the customer) between these 
different categories. 
Sociotechnical systems theory was chosen to be used in this thesis since it suits 
the research domain well, as it can be concluded when investigating the extant 
literature. The intention is to understand the complex domain of the medicine supply 
chain – which is labor-intensive, especially in the downstream (consisting of various 
stakeholders and technologies). The sociotechnical systems model can arguably be 
used to illuminate this interface, and the theory is particularly used in Articles II and 
III. 
 
4 Methodological Background 
4.1 Summary of the methodological background 
used in this thesis 
This research follows the qualitative, descriptive IS research approach, whereby 
Articles I–III are firmly descriptive. Article IV is more prescriptive by nature, having 
design science research elements. Descriptive emphasis is unavoidable, given that 
the research concerns elucidating a novel area. Descriptive research intends to 
answer “what” questions (de Vaus, 2001), and this is the aim. The main research 
theme is studying what is going on in the medicine supply chain arena and the role 
IS play in this. This could not be answered with a fully prescriptive study. 
Whereas Article IV is a pilot study describing a high-level, however concrete, 
solution, a wider design science and prescriptive research could follow this initial 
research – investigating, for instance, a problematic part of the supply chain and 
proposing a solution. As the field is novel, a descriptive model is needed to set the 
scene. This lays the foundation for future prescriptive studies and design science, as 
well as action research projects. 
The purpose of this research calls for using qualitative methods and an 
exploratory approach. The purpose is not to confirm a theory but rather explore and 
create the basis for theorizing within the area of medicine supply chain and IS. The 
research is based on multiple qualitative studies, including a targeted literature 
review, an observational study, a case study and a design science-based study 
examining the area from different perspectives. This enabled building an overview 
of the complex phenomenon and allows some theory proving along the way. It was 
anticipated that the research questions would be refined in the course of the research; 
hence, the objective was not to test the same detailed hypothesis with multiple cases 
but rather to accumulate knowledge and understanding through various studies and 
enable building detailed hypotheses at a later stage. 
The main methodological approaches that steered this research are in this 
chapter: descriptive qualitative research, IS research, IS case study research and 
design science research. 
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4.2 Qualitative methods in IS research 
According to Galliers and Huang (2012), although being not uncommon, qualitative 
research is not dominant or even equivalent to the volume of quantitative research in 
IS research if measured by the number of articles in top journals. The reasons for 
this are many, including the lack of education (there are more quantitative courses 
available) and the rejection and negative attitude toward qualitative articles (Conboy, 
et al., 2012). One aspect is the difficulty of qualitative research. It is based on tacit 
skills difficult to train to novice researchers, which leads to a vicious circle with less 
qualitative practitioners and more rejection toward qualitative research (Galliers & 
Huang, 2012). 
According to Crabtree and Miller (1999), the aim of scientific research is 
identification, description, explanation generation, explanation testing or control. 
The first three are exploratory by nature and often researched inductively using 
qualitative methods, while the last two are often quantitative research–driven. It is 
common sense that the last two are based on deductive approach, whereby data are 
evaluated utilizing a general theory. This contrasts with inductive approach, whereby 
generalization and theory follow the data. 
Whether induction can be a truly objective task can be argued. Some argue that 
induction cannot take place in isolation to the researcher’s background, previous 
knowledge, aims and so forth (Srivastava & Hopwood, 2009). It is rather 
subjectively contextualized, whereby the researcher’s knowledge, skills and 
experience heavily affect the reasoning (Ketokivi & Mantere, 2010). Qualitative 
approach does, however, not necessitate an interpretive position (Conboy, et al., 
2012). There are, for instance, positivist case studies. 
Qualitative research often follows an iterative process, whereby analysis, data 
collection and explanation are repeatedly revisited. More than a feature of qualitative 
methods, this relates to the interpretive approach. In contrast to positivist research, 
which is usually waterfall-like and progresses linearly from the problem statement 
to the hypothesis, the interpretive approach requires a more reflective position, 
whereby the knowledge is accumulated incrementally. In the course of iterations, 
while receiving more information and interpreting it, even the research question may 
be refined to be more relevant (Crabtree & Miller, 1999). Practically, when analyzing 
the data, the researcher needs to ask themselves what the data are telling, what is it 
that is required to be known and how these two are linked (Srivastava & Hopwood, 
2009). Answering the last question may lead to refining the focus and research 
questions. 
This is also the approach in this thesis. The research theme was iteratively refined 
and clarified during the project after more knowledge on the arena was gained. Data 
were collected in multiple ways, including interviews, observations, questionnaire, 
extant literature and other documentation (including annual reports), and the work 
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progressed inductively. It can be argued that a novel area, such as the intersection of 
medicine supply and IS, gains from the inductive approach. Since the aim is to 
outline and explore a wide area, one cannot restrict oneself to nor tie oneself too tight 
to a predefined theory. This is not to say that there would not be any theoretical basis 
but, rather, a theoretical frame – that is, the sociotechnical systems and information 
asymmetry concepts have been utilized when interpreting the data collected in 
multiple exploratory cases. 
Rather than a fully interpretive, the approach could be called aparadigmatic, 
whereby one is not strictly restricted to certain methods and research settings. 
Perhaps functionalism, as defined by Burrell & Morgan (1979), would be close in 
some respects – such as a status quo–seeking approach, with an emphasis on 
management viewpoint and the deterministic standpoint. The differences are in the 
idiographic and interpretive approaches adopted throughout the study. This thesis 
also utilizes design science. 
According to Goldkuhl (2012), the pragmatist paradigm suits the needs of design 
science. Pragmatism values actions in its ontology, and its priority is to help local 
practices through practical interventions. The pragmatist researcher assumes a 
participatory role, and pragmatism can be understood to be located between the 
positivist and interpretivist positions, which would also describe the approach 
assumed in this thesis. 
4.3 Descriptive and prescriptive approaches and 
design science in IS research 
According to March and Smith (1995), IS have been studied from two perspectives: 
descriptive and prescriptive. The former aims at creating understanding about IT and 
its usage. The latter aims at giving guidelines for IT practice. Whereas descriptive 
research is typically associated with traditional sciences, prescriptive research is 
associated with design science. March and Smith (1995) argued that the descriptive 
approach has traditionally been conceived as “real science,” and the prescriptive 
approach as “less scientific.” Design science has, however, had its place in IS 
research – given the special nature of the research domain: an area studying 
technology, organizations, governance and individuals, as well as heavily emerging, 
only having begun some decades ago and now adopted ubiquitously. 
This thesis is descriptive by nature, as it intends to map out medicine supply and 
the IS area. The intention is not to provide a set of blueprints for implementation but 
rather to understand the wider concept and its main features. It is the follow up work 
that can be more prescriptive. Some prescriptive features, however, can be found in 
the thesis: Article IV utilizes the design science approach when introducing a 
Teijo Peltoniemi 
52 
concept for managing scarce information and risks in the plasma derivatives supply 
chain. 
According to van Aken (2004), design science is an acknowledged form of 
science in the fields of engineering and medicine, whereas it is not so in social 
sciences. In the social science arena, explanatory approach is still conceived as a 
more rigorous science. According to the critique, the problem with explanatory 
approach – as compared to, for example, design science research – is its objective to 
create predictive and general theories. This can lead to banal theories with no real-
world use. 
 Design science aims at creating general-purpose constructs and models, where 
the researcher’s position is less interpretive and external to the research topic at hand 
(Iivari & Venable, 2009). Design science contains evaluative actions for examining 
the context, the construction of artifacts and, finally, actions to evaluate the artifacts. 
The value of the research is determined based on the value it produces to those 
adopting and using the artifacts in real life. According to the design science position, 
creating new knowledge is considered futile if it does not generate any practical 
benefit. The design also must be innovative and new (March & Smith, 1995). The 
concept introduced in Article IV matches these criteria. 
4.4 Case studies within IS research 
It can be argued that the IS field is pervaded by fast-paced technological 
development that often keeps practitioners ahead of academic researchers. This has 
led researchers to examine current practices instead of identify future directions that 
would be implemented by practitioners (Benbasat, et al., 1987). Idiographic research 
strategy (i.e. one that seeks to understand phenomenon in its own settings) seems to 
be suitable for this kind of problem area (Benbasat, et al., 1987). This is the reason 
Bensabat et al. (1987) suggested that case study is a viable method in IS research. 
Case studies allow researchers to answer “how” questions, which are typical 
when exploring novel and emerging research topics with limited prior knowledge 
(this is not to say that “what” questions cannot be answered with case studies). 
Typical research topics in ISS examine the interfaces between humans, organizations 
and technology (Dube & Pare, 2003). Understanding these complex and emerging 
environments – such as the intersection of medicine supply chain and IS areas, which 
is investigated in this thesis – require interpreting rich and varying data. 
Bensabat et al. (1987, p. 371) summarized common characteristics for case 
research, including the following: 
1. Phenomenon is examined in a natural setting. 
2. Data are collected by multiple means. 
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3. One or few entities (person, group, or organization) are examined. 
4. The complexity of the unit is studied intensively. 
5. Case studies are more suitable for the exploration, classification and 
hypothesis development stages of the knowledge building process; the 
investigator should have a receptive attitude towards exploration. 
6. No experimental controls or manipulation are involved. 
7. The investigator may not specify the set of independent and dependent 
variables in advance. 
8. The results derived depend heavily on the integrative powers of the 
investigator. 
9. Changes in site selection and data collection methods could take place as the 
investigator develops new hypotheses. 
10. Case research is useful in the study of “why” and “how” questions because 
these deal with operational links to be traced over time rather than with 
frequency or incidence. 
These are quite well aligned with those specified by Dube and Pare (2003). For 
example, the research target is a contemporary phenomenon related to an entity such 
as an organization, person or technology, which is researched in its complexity in 
real-life circumstances and integrated into its context with no controlled observation 
involved. 
When considering this thesis, many of these characteristics match. This research 
studies a contemporary phenomenon in natural settings; data are collected from 
multiple sources and integrated and then interpreted by the author, building a new 
concept. There are no experimental controls or independent variables in play. 
Case research can be categorized according to the paradigm (Dube & Pare, 
2003). In other words, case studies can be conducted from the positivist or 
interpretive perspective or critical perspective – which could, for instance, be that of 
critical realism. Another categorization is explanatory vs. descriptive. According to 
Dube and Pare (2003), the former is theoretically grounded, whereas the latter aims 
at merely describing a phenomenon. Explanatory case research takes a positivist 
stance, with hypothesis testing as a priority. Conversely, descriptive case research 
explores a phenomenon – the case, aiming to create an interpretation. The emphasis 
in case research has traditionally been on the latter. 
The third category Dube and Pare (2003) introduced is exploratory case study. 
This resembles the descriptive approach but has a clear theoretical foundation, 
whereas descriptive case study often has none. The categorization follows that of 
Yin (1994), which is a highly influential and cited source. Exploratory case studies 
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often answer to “what” type research questions (Tellis, 1997) and suits therefore the 
requirements of this research, which intends to explore what the impact of 
digitalization on the medical supply chain is. According to Dube and Pare (2003), 
single case study is dominant in IS research. Whereas explanatory case research 
would require a multiple case approach due to reliability and validity questions, in 
cases of exploratory and descriptive case studies, it can be argued that a single case 
approach suffices. 
4.5 Reliability and validity 
Reliability and validity are attributes labeling the quality of scientific research but 
coined in association with positivist quantitative research. According to Koskinen, I. 
et al. (2005), traditional means for assessing reliability and validity are not applicable 
in qualitative research in the same way they are applied in quantitative research. 
Eikeland (2006) argued that validity as a concept in social sciences does not have a 
sound foundation and can be philosophically questioned from many aspects. 
According to him, demanding validity is especially problematic since it assumes 
there is a natural state the organization under research operates in and which may 
become disrupted by the research group. Furthermore, it assumes that the operation 
is structured around controllable causes and effects. Validity also assumes complete 
objectiveness from researchers, and finally, it should not be regarded as a problem 
that research subjects – humans – are treated as external objects. 
Although this is an interpretive and qualitative study, these questions require 
discussion. To answer the reliability question, various actions were taken. Article I 
is based on multiple literature sources, whereby each of the explanations given as 
the result of the study are based on multiple sources. Through this, the researched 
topics are examined from multiple perspectives, and none is based on a single source 
that could be easily conflicted by other sources. Article II is based on data collected 
from multiple pharmacies and therefore relies on one case only. Article III is based 
on semi-structured interviews and a survey – whereby the same questions and themes 
are, again, asked from multiple respondents. This is backed up by data sources such 
as annual reports. Conversely, Article IV relies on multiple sources. 
In terms of validity, the question is harder. As per Eikeland (2006), an entire 
sociotechnical concept with various stakeholders, interfacing entities and underlying 
structures is examined, and therefore, isolating the research target from its 
surroundings, and one as a researcher from the research target, is challenging, if not 
impossible. Rather than proving a hypothesis based on natural science criteria and 
units in a controlled environment, in this study, the researcher interprets the 
knowledge accumulated through the process. However, one form of validity can be 
enforced: content validity. According to de Vaus (2001, p. 30), “Content validity 
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evaluates how well the measures tap the different aspects of the concept as we have 
defined it.” The concept – that is, the medicine supply chain – was investigated from 
several aspects; hence, it can be argued that content validity was achieved. 
 
5 Summary of Research Articles 
5.1 Summary of data strategies 
In this research, multiple data collection methods were utilized in each of the studies. 
Article I is based on extant literature, and it aims at building a concept. Article II 
utilizes quantitative data collected through observing the dispensing process in 
pharmacies. This is combined with extant literature. Article III is based on multiple 
interviews, a survey and background documentation study. Article IV is again based 
heavily on extant literature, while the concept is built using the design science 
approach. 
This research follows explanation building strategy – which, according to Yin 
(1994), is one of the main analysis strategies in case studies. This is an iterative 
process whereby an initial theoretical proposition is compared to findings. This often 
leads to revising the proposition and involves multiple cases – which are, 
subsequently, compared to the revision. In Article I, an initial model was created 
based on the information asymmetry concept, and the extant literature was analyzed 
to explore this model. Article II built an overview and explanation of how 
pharmacies have digitalized after ePrescription, basing on the theoretical frame of 
sociotechnical systems. In Article III, knowledge on the medicine waste area was 
accumulated iteratively, and this was then used to answer the thematic questions 
raised at the beginning of the study. Article IV is slightly different, given its design 
science approach; the analysis of the extant literature culminates in a concrete model. 
Overall, this thesis investigates the medicine delivery from various aspects 
through the four studies. This assures an adequate coverage. Considering the specific 
articles, Article I is based on a targeted literature review, covering a multitude of 
sources used to investigate the research topic from various aspects. Article II utilized 
data collected from multiple pharmacies. For Article III, again, a multitude of 
sources were utilized, whereby the research arena and themes were outlined through 
multiple open interviews and observation in the first place. Article IV was 
coauthored with an industry subject matter expert that supports ensuring the 
relevance of the designed artifact. 
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5.2 Article I: Information asymmetry as a key 
problem in medicine delivery 
Article I is titled The digitalization of the Medical Value Network – How Information 
Asymmetries Can Be Managed with Digital Innovations. The aim of the article was 
to conceptualize the medicine supply chain through building a model for the chain 
and investigating it based on extant literature. The article studied how technology is 
used in the supply chain and how it specifically mitigates the problem of asymmetric 
information. Another theoretical basis it utilized is the value network theory. It was 
published in the International Journal of Telemedicine and Clinical Practices 
(Vol. 2, No. 4) in 2017. The summary of Article I is presented in Table 3. 
Table 3. Article I. 
TITLE The Digitalization of the Medical Value Network – How Information 
Asymmetries Can Be Managed with Digital Innovations 
PUBLICATION DATA Peltoniemi, T., 2017. International Journal of Telemedicine and 
Clinical Practices, 2(4), pp. 298–317 
THEORETICAL 
BASIS 
Information asymmetry, value network 
METHOD Targeted literature review and interview 
RESEARCH 
THEMES 
How can incomplete information and information asymmetries in the 
medical value network be managed? 
How can digital tools support this? 
RESULTS Based on multiple examples across the value network, including 
ePrescription, electronic health records, generic substitution, 
automatic dispenser technology, outcomes-based methods, online 
medical information and medicine demand management, it can be 
argued that technology and digital tools can play an important role in 
managing information asymmetries, and equalizing information 




The purpose of the article was to set the scene in terms of building the concept of 
medicine delivery chain – forming the basis for the model, as illustrated in Figure 3, 
and mapping out challenges. Therefore, the article was largely based on studying 
extant literature. The study discusses key sources (e.g. (Akerlof, 1970), (Arrow, 
1963)) in information asymmetry and how the medical market is especially subject 
to it. Conversely, the value network is used as a theoretical basis to model the supply 
chain. 
The value network is a network of parties producing a service or a product (i.e. 
value) for a customer (Stabell & Fjeldstad, 1998), and information flows are the 
lifeblood of the network  (Sherer, 2005). Information is an asset, and those having 
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more of it have been powerful actors in the network. Digitalization can, however, 
change this, as it makes information available at low cost through digital networks 
(Spence, 2015). This changes the dynamics in various industries and related value 
networks. 
A model of the medicine supply value network is outlined in Figure 8. Whereas 
this is a simplified view to the network, it contains the main pharmaceutical actors – 
that is, from the medicine manufacturing industry to the customer (i.e. patient) – and 
should illustrate the idea. 
 
Figure 8. Medical value network. 
 Several possible unequal information positions can be identified in this network 
(it is worth noting that these are risks that may or may not realize). For example, the 
medical market is subject to supplier-induced demand, whereby physicians may 
prescribe treatments that are not really needed and the patient has no means of 
evaluating this. The physician’s prior performance is also unknown to the patient. At 
the same time, neither the physician nor the insurance company can be sure that the 
patient will follow the prescription. A major asymmetry is the one inherent in the 
entire health concept – the patient themselves is the expert in their condition, as they 
are the one experiencing it. 
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Moving up the stream, the service providers are uncertain of their medicine stock 
levels and keep ordering medicines – which, given incomplete expiry information at 
the wholesalers’ end, become rapidly expiring stocks and waste. Wholesalers’ 
information on their stock levels, however, may also be inaccurate, leading to 
pharmacies ordering expiring products. 
An entirely different discussion is demand management. There are currently 
several challenges in predicting the demand, which leads to shortages. For example, 
during the time of writing, the world was facing the COVID-19 pandemic. This led 
to shortage of respirator masks, for example, and a surge of substandard products 
entering the market (Yu, 2020). Although predicting the pandemic a year ahead 
would have been impossible, the medicine supply chain organizations failed to read 
the signals when the virus outbreak began, which would have allowed them more 
time to prepare. 
There also are many other uncertainties, as well as information asymmetries, in 
the supply chain. For example, it is beneficial for a pharmaceutical manufacturer to 
hide information on ex-factory prices, as it increases their negotiation power in 
different markets. For counterfeit product vendors, it is beneficial to hide information 
on the origins of products. Not all problems are information asymmetries per se but 
rather uncertainties and a lack of transparency. 
What can be argued here is that this incomplete and unequal information creates 
significant inefficiencies in the market and burdens the economy. For example, 
annual expenses relating to prescription noncompliance to the US economy are 
estimated at USD 300 billion (Foo, et al., 2011) and relating to the lack of generic 
substitution is estimated at USD 9 billion (Stenner, et al., 2010). Wasted prescription 
medicines burden the UK economy with GBP 300 million annually (Hazell & 
Robson, 2015). 
Regarding other markets, it can be observed that digital platforms have equalized 
information between buyers and sellers through new kinds of trust mechanisms 
(Spence, 2015). Uber and AirBnB users rate each other, for example, and microloans 
markets are based on self-policing rather than mediators and regulations. 
Traditionally, regulations have mitigated information asymmetries, whereby 
regulators act as mediators preventing any one side from exploiting their power 
position. It can be argued that digital technologies can smoothen transaction costs 
through increased monitoring capabilities (Varian, 2010). Table 4 summarizes 
various technologies that are or can be used to manage information asymmetries in 
the medicine delivery domain. 
Teijo Peltoniemi 
60 





Electronic Health records 
Blockchain 
Generic substitution Generic substitution system 
Reference pricing system 
Online medicine information 
Medicine pricing databases 
Automatic dispensing 
technology 

















Automatic medicine dispenser 
 
 
 The contribution of this article to the thesis is twofold: First, this article sets the 
scene through outlining the medicine delivery supply chain model (Figure 3). 
Second, the article investigates the model through the lens of information asymmetry 
to highlight challenges and potential solutions. The knowledge gained in this study 
is utilized in later phases of the thesis through taking the investigation to a more 
granular level. 
5.3 Article II: The digitalization pattern in 
pharmacies 
Article II considers how Finnish community pharmacies have digitally transformed 
in the past decade. The trigger for the digitalization was ePrescription, which was 
rolled out in Finland from 2012 onward and regulated by law. The research 
especially focuses on the sociotechnical impact of the digitalization. The article has 
been submitted to BMC Health Services Research, and the details are outlined in 
Table 5. 
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Table 5. Article II. 




Peltoniemi, T., Suomi, R., Lähteenoja, M. & Peura, S. Submitted to 
BMC Health Services Research 
THEORETICAL 
BASIS 




What is the impact of ePrescription to the dispensing process? 
How does digital transformation impact pharmacy practice? 
RESULTS The dispensing process has significantly changed as a consequence 
of the ePrescription, which has been one of the main triggers for the 
digital transformation in pharmacies. Sociotechnically, this new 
technology is shaping the working practices and tasks to more 
prescribed and regulated from workers’ point of view.  
 
 
 The study was based on observing the dispensing process before and after the 
deployment of ePrescription. Pharmacy practices have been disrupted by not only 
ePrescription but also the so-called direct dispensing model, which has also been 
rolled out in pharmacies. This entails that the medicine is dispensed to the customer 
immediately in the customer service event, rather than the pharmacist preparing the 
delivery and calling the customer to pick it up. 
According to the study, these changes have made the dispensing process faster. 
In addition, the digitalized process seems more predictable and more tightly 
governed. Sociotechnically, this implies there is less freedom to improvise, which 
changes the work environment of the pharmacy staff. Regulations form a significant 
factor – as ePrescription, which is based on laws and regulations in Finland (Laki 
sähköisestä lääkemääräyksestä [Electronic Prescription Act] 61/2007), is the trigger 
for the digital transformation. 
One of the drivers of ePrescription is the increased visibility and understanding 
of a patient’s overall medication regimen and the increased role a pharmacy can take 
in the treatment. Therefore, one would consider that counseling time would increase 
in the pharmacy, but this is not visible in the results. However, the research implies 
that digitalization can increase efficiency in terms of the working processes across 
the medicine supply chain and that these may have sociotechnical implications, such 
as bringing tighter structures to work processes. 
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5.4 Article III: The consequences of poor 
information in medicine delivery in practice 
Article III focuses on medicine waste management and is titled Eliminating Medicine 
Waste in a Finnish University Hospital – A Qualitative Study. The study 
investigated, at a more granular level, one of the challenges identified in Article I. 
The article was published in Journal of Pharmaceutical Policy and Practice on 2 
October 2019. The details of the article are presented in Table 6. 
Table 6. Article III. 
TITLE Eliminating Medicine Waste in a Finnish University Hospital – A 
Qualitative Study 
PUBLICATION DATA Peltoniemi, T. & Suomi, R, 2019. Journal of Pharmaceutical Policy 
and Practice, 12, 27. 
THEORETICAL BASIS Sociotechnical systems model 
METHOD Interviews and survey 
RESEARCH THEMES How is medicine waste managed in hospital settings? 
How do social and technical subsystems support it? 
RESULTS The bottlenecks in the technical system include poor quality of data 
across the medicine delivery chain, covering wholesalers, pharmacy 
and wards, and weak support of information systems, which reduce 
the ability to efficiently manage the waste. The pharmacy staff seeks 
to compensate this with informal practices. 
 
 
 This article highlights, again, how incomplete information accumulates through 
the medicine delivery chain. In a ward, inventory is often maintained manually and 
inaccurate. This leads to ordering approximate quantities of medicines from the 
central pharmacy. The central pharmacy combines orders and the inaccurate 
information received from wards when ordering from wholesalers, which often leads 
to expiring stocks of medicines that are not needed. The information of medicines in 
wholesalers’ stocks is also inaccurate, and they may dispatch medicines that will 
expire in a few days. Also, prescription recommendations and medication 
preferences may change, which is not communicated to wards or the pharmacy; this 
leads to the pharmacy stocking up with obsolete medicines. 
From the sociotechnical viewpoint, the IS support for work routines is 
inadequate. In addition to the poor quality of information, usability is often poor, and 
hospital staff try to avoid the cumbersome applications used across the medicine 
delivery chain. The processes are, hence, manual and reliant on the knowledge and 
skills of individuals. The main findings are summarized in Table 7. 
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Table 7. Main findings from Article III. 
FINDING DESCRIPTION 
Inconsistent expiry information  The medicine inventory in wards is maintained manually, 
and there is no accurate information on expiry dates. The 
expiry information on the wholesaler’s ordering system may 
be incorrect. 
Lack of integration As the IT systems are not fully integrated, staff need to 
manually cross-check information from various applications 
when estimating medicine demand and placing orders. Staff 
often avoid this manual task and base their estimations on 
previous orders and common sense. 
Lack of an official recycling 
scheme 
Recycling is not a managed process, and it is based on 
voluntary action and an unofficial email list. 
Poor usability of IT applications Applications appear unintuitive and onerous to use, which 
leads to further avoidance of their use. 
Infrequent ordering process  As the ordering process is a rather heavy, manual 
operation, it is more economical to order infrequently and in 
larger quantities than needed. 
Inaccurate metrics Accurate figures on medicine waste are unavailable, given 
that only medicines returned to the pharmacy are counted 
as waste. This leads to more confusion in terms of 
managing and reducing waste. 
 
 
 To cope with the shortcomings in the technical subsystem, the social system is 
emphasized. There are informal structures in place to facilitate recycling, for 
example. This is facilitated by an unofficial email list and such. Moreover, the 
pharmacy staff forms an inner circle for information sharing; those outside the inner 
circle may not be aware of these unofficial structures. 
It can be argued that the related IS are inadequate and unaligned with the needs 
of the work processes and the delivery organization. This is despite the decades-long 
research tradition, especially in the healthcare domain. Surely, sociotechnical 
viewpoint must have been part of the design practices of these systems; few IS are 
designed without considering users and their requirements. 
The issue seems to relate to the silo organization, whereby the end-to-end view 
of the process diminishes. Individuals across the supply chain execute what is 
expected in relation to their role, disconnected from each other. Not understanding 
the big picture or the economic impact of their actions, many may be tempted to 
work with estimates. This, combined with the poor availability of accurate data, leads 
to results with questionable integrity. 
Therefore, sociotechnically, the focus should be on the big picture, 
understanding the entire supply chain process both from technical and social 
perspectives in the hospital and surrounding organizations. Traditionally, 
sociotechnicality entails bottom-up style user-centricity, which is clearly inadequate 
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in many healthcare projects in which politically and organizationally complex 
networks are present. 
5.5 Article IV: How to manage information 
asymmetry with novel digital solutions 
Article IV’s focus is on the upstream of the medicine delivery chain, examining the 
blood plasma industry through investigating extant literature on distributed ledger 
usage in the healthcare and logistics domains. It identifies multiple risks relating to 
the plasma supply chain and suggests distributed ledger–based solutions. This article 
was published in Blockchain in Healthcare Today (Vol. 2) in 2019, and the details 
are presented in Table 8. 
Table 8. Article IV. 
TITLE Evaluating Blockchain for the Governance of the Plasma Derivatives 
Supply Chain: How Distributed Ledger Technology Can Mitigate 
Plasma Supply Chain Risks 
PUBLICATION DATA Peltoniemi, T. & Ihalainen, J, 2019. Blockchain in Healthcare Today, 
2. 
THEORETICAL BASIS Design science 
METHOD Extant literature, design science 
RESEARCH THEMES How is distributed ledger technology, such as blockchain, utilized in 
the healthcare domain? 
What are the risks in the plasma supply chain? 
How can blockchain be utilized to mitigate these risks? 
RESULTS The plasma supply chain is pervaded by incomplete data across the 
chain, which presents several risks. Blockchain and zero-knowledge 
proof technologies allow the reduction of the requirement for 
complete information between the supply chain partners and, 
hence, can be used to mitigate the risks. 
 
 
Plasma is used in the pharmaceutical industry to produce certain medicines  
(International Council for Commonality in Blood Banking Automation [ICCBBA], 
2018). Globally, it is a major industry, whereby the US is the biggest exporter 
(Transparency Market Research, 2018). The shortage of plasma has grave 
consequences, as several critical medicines cannot be produced without it. 
The supply chain is, however, vulnerable, as it is reliant on few exporters. 
Moreover, there are ethical questions to be considered since plasma-exporting 
jurisdictions often remunerate donors and this attracts addicts and other vulnerable 
individuals (The Economist, 2018). The effect of frequent donation to health is 
unknown. To mitigate these risks, it would be good to have more exporters of 
Summary of Research Articles 
 65 
plasma. However, there is a risk of falsification – whereby, for example, the origin 
of the plasma is blurred. Testing and disinfecting the blood is costly, and there may 
be a temptation to bypass this process. 
To mitigate these risks, an ability to govern the plasma supply chain is needed. 
Again, the information in the supply chain needs to be equalized to bring adequate 
transparency to the downstream of the delivery chain. However, it is often not in a 
commercial organization’s interest to openly disclose information on its business 
operations, so there should be a way to verify the key element – that is, the origin of 
the plasma – through disclosing the minimum amount of information. 
Article IV and the related study examines the role of a distributed ledger to tackle 
this problem. A distributed ledger is used in logistical operations and the medicine 
supply arena (e.g. (Center for Supply Chain Studies, 2017)). The key concept is zero-
knowledge proof, which enables verifying transactions with the least amount of 
information (Radocchia, 2018). This concept turns the question of information 
asymmetry upside down; rather than increasing the information, it removes the need 
for information. In the healthcare domain, this can be useful – as the related 
information is often of a sensitive nature and sharing it exposes various risks, such 
as those relating to information security, and sharing this data is therefore often 
restricted by law. 
 
6 Findings and Discussion 
6.1 Main findings 
This doctoral thesis investigated the medicine supply arena through modeling it 
conceptually, examining problems and bottlenecks across the delivery chain and 
suggesting some solutions to mitigate these problems. The main problems relate to 
the incomplete information and uncertainty, as well as asymmetric information, in 
the supply chain. This applies to specific parts of the supply chain, as well as the 
entire chain. For the latter, it is specifically the lack of an end-to-end view of the 
process, which generates uncertainty. 
The medicine supply chain can be modeled considering the pharmaceutical 
industry in the upstream and the patient as the end user in the downstream. The 
supply chain comprises many participants, including logistics providers, 
wholesalers, insurers, regulators, hospitals, pharmacies, healthcare service providers 
and so forth. The information is highly asymmetric between the participants, whereas 
the efficient supply of medicines would require more transparency across the chain. 
Some of the information asymmetries are illustrated in Figure 9 
 
Figure 9. Asymmetric information across the medicine supply chain. 
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In Figure 9, the problematic areas are identified with numbered asterisks: 
1. Pharmaceutical suppliers may seek to hide the origin of the supply or 
attempt to falsify it somehow. For example, the suppliers of plasma 
derivatives may seek to falsify testing practices. 
2. Pharmaceutical manufacturers may seek to hide information on pricing 
and product availability (Breen & Yaroson, 2018). For the former, the 
intention is to maintain profitable pricing in varying markets. For the 
latter, this may be carried out to create demand in the downstream of the 
supply chain. The incomplete information is propagated through the 
supply chain – creating supply chain disruptions, such as medicine 
shortage. The EU is currently deploying a regulation to mandate more 
accurate reporting of shortages and, therefore, increase the predictability 
of medicine supply disruptions (Milmo, 2019). Another information 
asymmetry risk relates to product falsification and counterfeiting. There 
are illicit manufacturers attempting to introduce counterfeit products into 
the supply chain, and they naturally aspire to hide the origin of the 
medicine. 
3. The data disclosed by wholesaler can be outdated or otherwise inaccurate 
– which may lead to pharmacies ordering medicines that expire shortly, 
leading in turn to wastage. Medicine wastage is a significant cost at the 
societal level – for example, in the UK, the annual cost of prescription 
medicine waste is GBP 300 million (Hazell & Robson, 2015). The 
wastage also has a grim environmental impact. Furthermore, incomplete 
or hidden information in upper parts of the supply chain can be propagated 
downward to wholesalers to drive prices up. 
4. Prescribers know more about treatments than laymen. Furthermore, 
usually, they solely hold the power to prescribe medicines. If there is 
scarcity of a prescribed medicine, the customer (i.e. the patient) needs to 
consult the physician to change the prescription. The customer is rarely in 
the position to assess the prescription and potential lower-cost 
alternatives. It is also challenging to estimate the past performance of the 
prescribed treatment to the given symptom. 
5. Patients may seek to hide their adherence to a prescription. This may be 
intentional or unintentional. Both are affected by attitudes toward 
treatment. The cost of nonadherence is high – for example, it is estimated 
to cost USD 300 billion annually in the US (Foo, et al., 2011). In the same 
way, patients may seek to hide information about their behavior from 
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insurers and other stakeholders. At the same time, the patient is always 
the best expert in their condition. 
6. In hospital settings, medicine delivery is often pervaded by incomplete 
and inaccurate information. To name just a few issues, the inventory of 
stocks is often inaccurate, there is no visibility of future demand of 
medicines and the medicine ordering staff may not know about preferred 
treatments, which all lead to ordering wrong quantities of potentially 
wrong medicines. This leads to both wastage of some medicines and 
shortage of others. 
Based on the above, the issues can be categorized as upstream challenges, 
involving the pharmaceutical industry–related stages; supply chain challenges, 
involving the logistics and wholesaler stages; and prescriber challenges, patient 
challenges and downstream challenges, involving healthcare units and pharmacies. 
Various tools can be used to manage these challenges – for example, regulations are 
required in this field to manage the adverse effects of information asymmetries. 
However, if the focus is on digital solutions, some upcoming or current solutions to 
ease these challenges are listed in Table 9. The key is better data transparency, as 
also demanded by other authors more recently due to the COVID-19 pandemic (Dai, 
et al., 2020). 
Table 9. Digital solutions in the medicine delivery arena. 
THE PROBLEM AREA SOLUTIONS 
Upstream challenges Blockchain and zero-knowledge proof 
Better quality information on pricing 
Supply chain challenges Better quality information on stocks and 
inventories 
Better quality information shared on 
disruptions 
Prescriber challenges Outcomes-based medicine and solutions to 
facilitate it 
More information available on treatments and 
physician performance 
Patient challenges Automatic dispenser 
ePrescription 
Wearables and similar solutions to monitor 
prescription adherence 
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 Another viewpoint is how to obtain a situational view to the entire process, 
producing visibility of each of the problem domains, from upstream to downstream. 
Considering wider issues such as medicine shortage, they may relate to, and be 
caused by, many problem areas across the supply chain. 
For example, according to Heiskanen et al. (2017), medicine shortage in Finland 
is usually caused by multiple issues, such as the small size of the pharmaceutical 
market, fluctuating demand, small stock sizes, long delivery times and complex 
supply chains. Therefore, to manage the shortage, a situational view of the entire 
chain, rather than just one part of it, is required. Situational awareness concerns 
observing the environment, understanding the situation, projecting the future 
situation, deciding the course of actions and performing those actions (Endsley, 
1995). In terms of the medicine supply chain, this means understanding the demand, 
as well as supply, to the level where failing supply chain nodes, such as 
manufacturing plants and distribution entities, can be identified in a timely manner, 
allowing precautionary actions to be taken. If the current situation is not understood 
and predictions cannot be made, researchers are left reacting to events that have 
already occurred, with no control of the situation whatsoever. 
In a wider domain, such as the supply chain, it has been difficult to obtain the 
situational view due to the lack of sophisticated analytical tools, and it has been hard 
to predict the demand or the disruptions in the production chain. However, predictive 
solutions have emerged and allow managing supply chain risks. Predictive solutions 
can involve multiple data sources, such as news feeds, device data, social media and 
data sources of global institutions, incorporated with production data and alerts on 
potential disruptions along the production chain (e.g. (KPMG, 2019)). 
Data and analytics-based tools have also been introduced to increase visibility 
and simulate processes. It has been suggested, for example, that process mining – a 
technique for discovering and analyzing business processes based on data, rather 
than manually – is a useful tool in healthcare settings due to the complexity and 
variability of the process environment (Erdogan & Tarhan, 2018). Medicine supply 
processes are equally complex and, hence, could benefit from process mining. 
6.2 Discussion 
Turning attention to the sociotechnical perspective, many discussion points can be 
identified. A key question is as follows: Why do many healthcare digitalization 
projects keep failing despite the strong footprint and long tradition of the 
sociotechnical approach? If the challenges introduced in this thesis are especially 
observed, they have not been solved to date. Many sociotechnically viable solutions 
seem to require more data and more information available in real life. 
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A key issue with the medicine delivery domain is that it is siloed. Some actors 
in the network benefit from this – for example, firms and businesses tend to 
maximize their profits, and this may entail hiding information, such as that relating 
to pricing or product availability. Conversely, if sociotechnically optimal solutions 
in intersecting organizations require this information to be available, this results in 
an problem that cannot be solved with any design, no matter how user-centric. 
Another viewpoint here is more philosophical. Idealistically, to maximize the 
efficiency of the medicine delivery, individuals’ behavior and, for example, how 
they follow prescriptions need to be monitored. This is also called surveillance, and 
this word has a negative connotation to many. Mandating people to continuously 
disclose data of their behavior would seriously jeopardize their privacy. This is 
where care is required since it is likely that people would consent to the use of their 
data with no objection without realizing all the potential outcomes of this action. 
One could also challenge the pervading emphasis on protecting current practices. 
If researchers always consider existing structures and how they need to 
accommodate those in new developments, there is a danger that they are tied to an 
old practice and cannot deliver impactful change. Transformation programs are 
deemed to remain meek digitization exercises rather than being truly 
transformational digitalization. In domains such as healthcare and medicine delivery, 
this is a risk, as solving the dilemma of sustainability in aging societies requires 
exponential change. 
It may not be the aim of the sociotechnical systems approach to hinder 
innovation, but there is a risk it becomes such. Emphasizing the social system in the 
design should not become a structure to maintain status quo. Those new practices 
needed to transform industries require drastic changes in organizations, roles and 
ways of working, and researchers cannot adhere to old ways by using the excuse of 
sociotechnical designs. 
One of the viewpoints is that researchers need to consider solutions that require 
less information rather than increasing the information in the design of a new system. 
A good example is the zero-knowledge proof concept. This allows verifying 
transactions without revealing data about it, undoubtedly a useful concept in a 
domain with sensitive data. This kind of design is difficult to come by if the design 
is based on user-centricity. Zero-knowledge proof is based on DLT, a technology 
that is mainly invisible for the everyday user, and many uses of the technology have 
been suggested in the healthcare domain (e.g. (Chawdhuri, 2019)). 
Electronic Health Record (EHR) systems have existed for decades, and 
standardization work has been carried out also for a long time – for example, HL7, 
the global healthcare data exchange standard was initiated in 1987 (Oemig & 
Snelick, 2016). However, researchers still struggle with designing a computerized 
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prescribing system that can support pharmacies and physicians in finding the right 
medicine and help pass the prescription safely to the pharmacy (Schiff, et al., 2016). 
The siloed nature of the healthcare domain is hard to overcome; it is a complex 
network. First, it is required to regulate across the supply chain to manage the 
information asymmetries. Second, it is required to innovate new digital solutions that 
reduce the impact of asymmetric information through identifying potential data 
sources across the supply chain and facilitating information sharing. Where this is 
challenging due to confidentiality and data privacy reasons, it is required to learn to 
make use of scarce and scattered data across the supply chain in innovative ways and 
reduce the need for complete information. 
6.3 Theoretical and practical implications 
In this thesis, it was described that the medicine supply chain operates with scarce 
and incoherent data, which hamper the efficient operation of the supply chain. 
Expanding medicine costs, especially in countries with aging populations and 
because of global pandemics, are likely. The medicine supply chain is prone to 
disruptions, and there is no control or transparency to efficiently manage it. 
For the practical implications, first, there is an urgent requirement to increase 
transparency across the supply chain. This entails identifying what data are available 
from across the supply chain and utilizing them to simulate the supply chain. This 
allows identifying and analyzing bottlenecks, improving the process and intervening 
where applicable. The regulatory work needs to continue and ensure that the data 
become increasingly available in a timely manner across the supply chain. The policy 
work should focus on the upstream of the global supply chain; this requires a 
thorough mapping out of the chain and associated risks and aiming the regulatory 
work to where it will have the most impact. Whereas the emphasis in the regulatory 
discussion may have been around patient and personal data, it is imperative that the 
data across the chain, covering the upstream and distribution, become more open. 
This cannot happen unless determined global regulation work is performed. 
Second, predictive models need to be deployed to allow better preparation for 
disruptions in the supply chain. This, again, requires data availability. It is nationally 
and regionally important that researchers can utilize global data sources – which are 
increasingly available – and form predictive models to be better prepared for 
disruptions. It is clear that the discussion on complex and fragile supply chains with 
single points of failures will take place and the global medicine supply chain in its 
current shape will be reconsidered. 
Whereas the priority needs to be in taking better control of the entire supply 
chain, multiple digital solutions can continue to be utilized to facilitate specific parts 
of the medicine supply chain – contributing to patient experience and empowerment, 
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for example. However, the impact on the bigger picture remains cosmetic unless the 
entire supply chain is fully understood and continued to be regulated strictly. 
Theoretically, it has been described how information asymmetry forms a major 
hindrance to the medicine supply chain and how digital solutions can contribute to 
overcoming it. Managing the incomplete information is, undoubtedly, one of the 
main drivers of the digital transformation in this domain. 
The applicability of the sociotechnical systems model in the design of new digital 
solutions is, however, questionable, as the user-centric approach often leads to status 
quo–seeking solutions, whereas it is imperative to discover radical new ways of 
working. It should, however, be noted that the sociotechnical viewpoint can be 
beneficial to understanding wider and complex environments with many, sometimes 
conflicting, interests and regulations and a domain that is, eventually, quite personal 
and sensitive. This view certainly cannot be obtained through researching a 
miniscule phenomenon. 
6.4 Future research 
There is an opening for a design science-oriented research piece in which the 
mechanisms for improving transparency and predictability of the supply chain are 
designed and piloted. These could be based on identifying stakeholders and data 
points across the chain and designing predictive models based on those. This study 
should approach the topic in an out-of-the-box manner, whereby current practices 
are significantly questioned. This also applies to the user-centricity that many 
traditional systems design methods overemphasize. The user-centricity should be 
transformed to customer-centricity – whereby the outcome of the system matters, 
rather than the process to achieve it. Whereas this may seem like a harsh way of 
viewing the world, it is the way that enables discovering radical solutions for 
pressing problems. The shift should involve understanding what outcome is required 
and then investigating what inputs and processes are required. This may be entirely 
different from the current state. 
From the sociotechnical systems perspective, more research is required to adapt 
the model to better suit a modern, rapidly changing world. Current status quo–
seeking tradition may well not be suited to finding radical solutions required to 
manage disrupted environments and business areas. 
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